



(86) Date de dépôt PCT/PCT Filing Date: 2006/05/12
(87) Date publication PCT/PCT Publication Date: 2007/11/22
(45) Date de délivrance/Issue Date: 2013/02/05
(85) Entrée phase nationale/National Entry: 2008/11/06
(86) N° demande PCT/PCT Application No.: JP 2006/309602
(87) N° publication PCT/PCT Publication No.: 2007/132512

(51) Cl.Int./Int.Cl. *C12Q 1/00* (2006.01),
A61K 38/00 (2006.01), *A61P 31/00* (2006.01),
A61P 37/00 (2006.01), *C07K 16/28* (2006.01),
C12N 15/09 (2006.01), *C12Q 1/68* (2006.01),
G01N 33/483 (2006.01), *G01N 33/53* (2006.01)

(72) Inventeurs/Inventors:
MARUYAMA, KENTA, JP;
MATSUO, KOICHI, JP;
YASUDA, HISATAKA, JP

(73) Propriétaires/Owners:
KEIO UNIVERSITY, JP;
ORIENTAL YEAST CO., LTD., JP

(74) Agent: SMART & BIGGAR

(54) Titre : DETECTION D'UNE MALADIE INFLAMMATOIRE ET COMPOSITION DESTINEE A LA PREVENTION OU AU TRAITEMENT D'UNE MALADIE INFLAMMATOIRE
(54) Title: DETECTION OF INFLAMMATORY DISEASE AND COMPOSITION FOR PREVENTION OR TREATMENT OF INFLAMMATORY DISEASE

(57) **Abrégé/Abstract:**

A novel method for detection of an inflammatory disease and a novel composition for prevention or treatment of an inflammatory disease are provided. The method for detection of an inflammatory disease comprises using RANKL and/or OPG as a marker in a biological sample. The composition for prevention or treatment of an inflammatory disease comprises RANKL and/or M-CSF as an active ingredient.



Abstract

A novel method for detection of an inflammatory disease and a novel composition for prevention or treatment of an inflammatory disease are provided. The method for detection of an inflammatory disease comprises using RANKL and/or OPG as a marker in a biological sample. The composition for prevention or treatment of an inflammatory disease comprises RANKL and/or M-CSF as an active ingredient.

DESCRIPTION

Detection of inflammatory disease and composition for prevention or treatment of inflammatory disease

Technical Field

The present invention relates to a method for diagnosing or suppressing inflammatory diseases such as sepsis, allergies, and autoimmune diseases with the use of RANKL, which suppresses the production of inflammatory cytokines or improves the survival rate of an inflammatory animal model.

Background Art

In recent years, it is known even in surgical fields that humoral factors produced at excessive levels play important roles in formation of pathological conditions during the perioperative period of significantly invasive surgery or the acute phase of a medical emergency such as an infectious disease. It is extremely important to measure various humoral factors in order to gain early, comprehensive knowledge of a pathology that changes every day or every second under such invasion and to apply the understanding clinically. Studies concerning various humoral factors in the process of shifts from sepsis to multiple organ dysfunction syndrome (MODS, by which the functions of a plurality of organs are damaged) have drastically progressed together with the development of molecular biological techniques. Recent studies on MODS have been improved to indicate a study approach that involves analyzing the mechanism of damage at the cellular level and microenvironment or humoral factors, so as to get closer to the pathology. Specifically, based on the understanding that MODS cases are extremely analogous to each other in terms of onset mechanism or pathology even if the causes of MODS cases differ (e.g., an MODS case due to sepsis), the control of factors involved in

the shift to pathology that is developed much earlier before the onset of MODS has recently been emphasized. It can be said that clinicians and researchers are currently focusing on elucidation of the pathology of sepsis that occurs at the prestage of MODS and establishment of effective countermeasures against the pathology rather on treatment for MODS itself.

Humoral factors are useful as inflammatory markers. Specifically, CRP (C-reactive protein), TNF- α , IL-1, IL-6, IL-8, IL-10, MIP-1, HMGB-1, MIF, C5a, calcitonin, and the like are known (Marshall et al., Crit Care Med 31: 1560, 2003). It has been reported concerning CRP such that CRP is used in combination with the number of platelets or the like for evaluation of the prognosis of severe sepsis (Asayama et al., Keio J Med 47: 19 1998). It has also been reported that no significant differences are confirmed between sepsis and trauma (Endo et al., Journal of Infection 73: 197 1999). Hence, solid evaluation has not been established for CRP. Similarly, in the case of TNF- α or IL-6, while it has been reported that no significant differences have been confirmed between sepsis and trauma (Endo et al., Journal of Infection 73: 197 1999), it has also been reported that IL-6 is used as a prognosis marker for sepsis (Reinhart et al., Crit Care Med 29: 765, 2001). Thus, solid evaluation has not been established for TNF- α or IL-6. Moreover, it has been reported that IL-10 is effective (Ono et al., Am J Surg 188: 150, 2004), however, it cannot be said that the effects of IL-10 have been sufficiently verified through use. Involvement of MIF in acute respiratory distress syndrome (ARDS), bronchial asthma, or the like has been reported (Donnelly et al., Nat Med 3: 320, 1997; Rossi et al., J Clin Invest 101: 2869, 1998), but it is unknown whether or not MIF can be used as a marker. It has not been revealed if the above-mentioned humoral factors cause sepsis or are produced as a result of sepsis.

Inflammatory reactions are biological reactions that limit the spreading of damage to a living body due to invasion and repair such damage. They occur as nonspecific reactions against all injuries or invasions. Inflammatory reactions are actually

physiological biological reactions that take place in close association with neuroendocrine reactions, immunoinflammatory reactions, and coagulation-fibrolysis reactions.

Inflammatory reactions are expressed locally in the forms of flare, swelling, pain, heat, and the like, and they cause systemic reactions with fever, tachycardia, tachypnea, and increased number of leukocytes when invasion is significant. Such conditions are referred to as systemic inflammatory response syndrome (SIRS). Examples thereof include SIRS not associated with infection or the like, but rather with trauma, burn, pancreatitis, and states after significantly invasive surgery, as well as SIRS associated with infection due to bacteria, fungi, parasites, viruses, or the like. In particular, SIRS caused by infection is referred to as sepsis.

Inflammatory reactions are established by vasodilation, vascular hyperpermeability, leukocyte-vascular endothelial cell activation, or the like. These reactions are induced by complements, amine, kinin, prostanoid, cytokine, and thrombin that are nonspecifically produced as invasion proceeds. Localized inflammatory reactions are induced by local noxious stimuli. However, when biological invasion is significant, systemic escape of these inflammatory mediators (and in particular, cytokine and thrombin) takes place and then systemic vasodilation, hyperpermeability, and leukocyte-vascular endothelial cell activation are observed. Inflammatory reaction has stages of receipt of noxious stimuli, reaction, and repairment. When a systemic inflammatory reaction is sustained, the reaction does not reach the repairment stage, so that biological homeostasis fails. In such case, it is known that MODS is induced to lead the living body to death.

For defense against invasion in the living body, three systems, the nervous system, the endocrine system, and the immune system, undergo reactions while closely interacting with each other. The nervous and endocrine systems are activated as invasion proceeds, resulting in enhanced energy metabolism, gluconeogenesis, increased cardiac output, and the like. Thus, inflammatory reactions are systemically enhanced.

Meanwhile, cortisol is known to suppress the immune system and catecholamine is known to suppress the activity of NK cells or killer T cells, which are immunocytes. Bacterial infection or the occurrence of tissue damage activates the complement system or the blood coagulation system, along with which vascular endothelial cells are activated and phagocytic cells including monocytes, macrophages, and neutrophils migrate. Thus, inflammatory cytokines (composed mainly of TNF- α and IL-1) are freed from the damaged sites. With liberation of these inflammatory cytokines, protease or active oxygen, platelet-activating factors, and the like are also freed, forming the pathology of SIRS. Therefore, it is possible to consider that SIRS is also a pathological condition caused by hypercytokinemia (Riedemann et al., Nat Med 9: 517, 2003).

It has been reported that in the U.S. that about 750,000 persons are affected with sepsis yearly and 210,000 or more persons lose their lives due to sepsis (Wheeler et al., N Engl J Med 340: 207, 1999; Severansky et al., Sepsis 3: 11, 1999; Hotchkiss et al., N Engl J Med 348: 138, 2003). Furthermore, treatment for sepsis causes significant economic impact because of lengthy ICU hospital stays or increased amounts of resources used. However, although establishment of a therapeutic method against sepsis that is also referred to as high inflammatory cytokinemia has been attempted as an emergent issue throughout the world, no therapeutic method currently exists by which reduction of sepsis fatalities can be realized (Vincent et al., Clin Infect Dis 34: 1084, 2002). A therapeutic method has been reported recently by which significant improvement in the prognosis of severe sepsis can be achieved via administration of activated protein C (APC) (Bernard et al., N Engl J Med 344: 699, 2001). APC will be approved by the U.S. Food and Drug Administration (FDA) for the first time as a therapeutic agent against severe sepsis. However, the degree of effectiveness of APC is a slight rise in lifesaving rate of only approximately 6%-7%. Thus, sepsis is still considered to be a pathological condition with a very high fatality rate that is extremely

difficult to cure. Furthermore, activated protein C is an endogenous protein that activates not only coagulation-suppressing functions, but also fibrinolytic functions, thereby inhibiting thrombus formation or inflammation (DePalo et al., *Advances in Sepsis* 1: 114, 2001). In addition to the palliative effects of activated protein C, it is inferred that APC increases the risk of bleeding because of its features. In particular, intracranial hemorrhage is a severe adverse event. Thus, administration of APC necessitates sufficient care so that APC is administered in compliance with contraindicated conditions. Attempts that have been made other than the aforementioned attempts are as shown below.

(1) Large amounts of steroids: Application of large amounts of steroids has succeeded as a pretreatment for animals with endotoxemia or bacillaemia. Based on such successes, the effects of administration of large amounts of steroids to patients with septic shock have been examined in early clinical tests. However, in large-scale double-blind studies, validity has never been reported even in cases of administration of steroids during early development of septic shock (Meduri et al., *Sepsis* 3: 21, 1999; Bernard et al., *N Engl J Med* 317: 1565, 1987; Bone et al., *Chest* 92: 1032, 1987).

(2) Antiendotoxin antibody: Treatment with a specific antiendotoxin antibody has been examined using polyclonal human immunoglobulin G against heat-sterilized *E. coli* J5, mouse (E5) and humanized (HA1A) monoclonal antibodies against endotoxin lipid A, and the like. Patients with severe gram-negative bacterial infectious disease have been examined as subjects (Llewelyn et al., *Sepsis* 3: 39, 1999). Validity has never been confirmed in large-scale tests.

(3) Anti-TNF treatment: Anti-TNF treatment is neutralization therapy targeting TNF- α (inflammatory cytokine), which uses an anti-TNF monoclonal antibody and a soluble TNF receptor. It has been reported that survival prospects can be improved in many sepsis models via suppression of the effects of TNF- α (Tracey et al., *Nature* 330: 662, 1987; Pennington et al., *Clin Infect Dis* 17 (Suppl 2): S515, 1993). Although a plurality

of phase II and phase III clinical tests have been conducted, it has never been reported that survival rates have been improved by suppressing the effects of TNF- α with the use of anti-TNF treatment (Abraham et al., JAMA 273: 934, 1995; Reinhart et al., Crit Care Med 24: 733, 1996; Severansky et al., Sepsis 3: 11, 1999; Reinhart et al., Crit Care Med 29: S121, 2001).

(4) IL-1 receptor antagonist (IL-1Ra): IL-1 is also an inflammatory cytokine, but is known to induce many pathological conditions of sepsis (Ohlsson et al., Nature 348: 550 1990). Such effects can be suppressed with the use of IL-1Ra, which is a natural IL-1 receptor antagonistic substance. However, a lack of differences between a treatment group (group of treated patients) and a placebo group in terms of survival rate has been demonstrated by three tests (two double-blind tests) conducted for severe sepsis patients (Fisher et al., JAMA 271: 1836, 1994; Opal et al., Crit Care Med 25: 1115, 1997; Severansky et al., Sepsis 3: 11, 1999).

(5) PAF receptor antagonist (PAFra): Platelet agglutinating factor (PAF) is a phospholipid involved in cytokine release during sepsis. It has been demonstrated by two double-blind tests that PAF receptor antagonist (BN52021) does not significantly improve survival (Dhainaut et al., Crit Care Med 22: 1720, 1994; Dhainaut et al., Crit Care Med 26: 1963, 1998; Severansky et al., Sepsis 3: 11, 1999). It has been recently demonstrated again by a phase II clinical test using another compound (BB-882) that the compound does not significantly improve the survival of severe sepsis patients.

(6) Nonsteroidal anti-inflammatory drug: an antiprostaglandin drug, Ibuprofen, has been examined in three double-blind tests, but the usefulness of Ibuprofen has never been demonstrated in any of these cases (Bernard et al., N Engl J Med 336: 912, 1997; Severansky et al., Sepsis 3: 11, 1999).

(7) Bradykinin antagonist: Bradykinin is a bioactive peptide involved in cytokine release and changes in blood vessels during sepsis. Improvement in lethality with the use of a bradykinin antagonist has never been observed in two double-blind tests (Fein et

al., JAMA 277: 482, 1997; Severansky et al., Sepsis 3: 11, 1999).

As described above, although various therapeutic methods for sepsis have been advanced, suppression of the incidence rate has never been confirmed. Sepsis is still a disease for which reduction in the number of deaths therefrom has been impossible to achieve. Novel exploitation of preventive methods or therapeutic methods for sepsis are required.

RANKL, which is a ligand of RANK, is an osteoclastic differentiation-inducing factor and is known to induce osteoclasts from precursor cells of the macrophage system under coexistence with a macrophage colony-stimulating factor (M-CSF) (see Yasuda et al., Proc Natl Acad Sci USA 95: 3597, 1998 and Lacey et al., Cell 93: 165, 1998). Specifically, RANKL is produced by osteoblasts and binds to RANK on precursor cells of the macrophage system, so as to induce the cells to become osteoclasts. Furthermore, at this time, OPG (osteoprotegerin) structurally analogous to RANK suppresses the effects of RANKL, as a decoy receptor. In this manner, bone metabolism is controlled by balancing RANKL and OPG amounts. RANKL is a membrane-associated protein and a part thereof is present in blood in a soluble form. Some bone metabolism diseases confirmed with variation in the concentration of soluble RANKL (sRANKL) have been reported. The usefulness of RANKL as a bone metabolism marker has been suggested, and medical applications of RANKL have been examined (see Rogers et al., J Clin Endocrinol Metab 90: 6323, 2005 and see JP Patent Publication (Kohyo) No. 2004-526748 A; JP Patent Publication (Kohyo) No. 2002-509430 A; and International Publication WO98/46644). Moreover, discussion often takes place concerning RANKL based on the concentration ratio of soluble RANKL to OPG; that is, the ratio of the concentration of soluble RANKL to OPG. As described above, the role of RANKL in the bone metabolism system has been conventionally known; however, the functions of RANKL in the natural immune system have remained unclear and the biological meaning of soluble RANKL existing in blood has also remained unclear.

Disclosure of the Invention

Objects to be Achieved by the Invention

An object of the present invention is to provide a method for prevention or treatment of symptoms resulting from inflammatory diseases such as infectious diseases, allergies, and autoimmune diseases with the use of RANKL and to provide a composition for prevention or treatment. Particularly, an object of the present invention is to prevent death due to such inflammatory diseases and to treat such diseases. Moreover, an object of the present invention is to provide a method and a reagent for measuring the concentrations of membrane-bound and soluble RANKL and the concentration of OPG, and the like existing *in vivo* (e.g., in blood or in synovial fluids) as markers for prediction of the degree of inflammation and risks such as the lethality of inflammatory diseases.

Means to Achieve the Objects

As described above, the roles of RANKL in bone metabolism are known. However, the functions of RANKL in the natural immune system have not been elucidated and the biological meanings of RANKL existing in blood have remained unclear.

The present inventors have considered the possible involvement of RANKL in control of the natural immune system and then examined the action of soluble RANKL on macrophages. As a result, the present inventors have discovered that inflammatory cytokine production due to infection is suppressed in various macrophages because of the effects of soluble RANKL. Furthermore, based on the fact that the concentration of blood-soluble RANKL rapidly decreases within several hours after infection, while the concentration of OPG increases, the present inventors have discovered that soluble RANKL alone, OPG alone, or a combination of soluble RANKL and OPG can be a sensitive novel marker for infection. Moreover, the present inventors have discovered

that administration of soluble RANKL makes it possible to prevent septic shock due to a drug and that a soluble RANKL can be used as an agent for preventing inflammation or as an anti-inflammatory agent. Thus, the present inventors have completed the present invention.

The present invention is as follows.

[1] A method for detection of an inflammatory disease with the use of RANKL and/or OPG as a marker in a biological sample.

[2] The method for detection of an inflammatory disease according to [1], which is a method for detection of an inflammatory disease with the use of RANKL as a marker in a biological sample, comprising determining that a subject is affected with an inflammatory disease when the concentration of soluble RANKL in a biological sample is lower than that of a normal subject.

[3] The method for detection of an inflammatory disease according to [1], which is a method for detection of an inflammatory disease with the use of OPG as a marker in a biological sample, comprising determining that a subject is affected with an inflammatory disease when the concentration of OPG in a biological sample is higher than that of a normal subject.

[4] The method for detection of an inflammatory disease according to [1], which is a method for detection of an inflammatory disease with the use of RANKL and OPG as markers in a biological sample, comprising determining that a subject is affected with an inflammatory disease when the ratio of the concentration of soluble RANKL to the concentration of OPG in a biological sample is lower than that of a normal subject.

[5] The method for detection of an inflammatory disease according to [1], which is a method for detection of an inflammatory disease with the use of RANKL as a marker in a biological sample, comprising measuring membrane-type RANKL existing on a cell in a biological sample by a flow cytometric method.

[6] The method for detection of an inflammatory disease according to [1], which is a

method for detection of an inflammatory disease with the use of RANKL and OPG as markers in a biological sample, comprising measuring membrane-type RANKL existing on a cell in a biological sample by a flow cytometric method and then determining that a subject is affected with an inflammatory disease when the ratio of the amount of membrane-type RANKL measured to the concentration of OPG is lower than that of a normal subject.

[7] The method for detection of an inflammatory disease according to [5] or [6], in which the cell in a biological sample is a peripheral blood cell.

[8] The method for detection of an inflammatory disease according to any one of [1] to [7], in which the inflammatory disease is an infectious disease, an allergic disease, or an autoimmune disease.

[9] The method for detection of an inflammatory disease according to [8], in which the inflammatory disease is sepsis.

[10] A detection reagent for detection of an inflammatory disease with the use of RANKL and/or OPG as a marker, comprising an anti-RANKL antibody and/or an anti-OPG antibody.

[11] A detection reagent for detection of an inflammatory disease with the use of RANKL and/or OPG as a marker, comprising an anti-RANKL antibody and an anti-OPG antibody.

[12] The detection reagent for detection of an inflammatory disease according to [10] or [11], in which the inflammatory disease is an infectious disease, an allergic disease, or an autoimmune disease.

[13] The detection reagent for detection of an inflammatory disease according to [12], in which the inflammatory disease is sepsis.

[14] A composition for prevention or treatment of an inflammatory disease, comprising RANKL and/or M-CSF as an active ingredient.

[15] The composition for prevention or treatment of an inflammatory disease according

72813-305

to [14], comprising RANKL and M-CSF as active ingredients.

[16] The composition for prevention or treatment of an inflammatory disease according to [15], in which the composition for prevention or treatment of an inflammatory disease is a combination preparation.

[17] The composition for prevention or treatment of an inflammatory disease according to [15], in which the composition is a kit comprising a drug that contains RANKL and a drug that contains M-CSF.

[18] The composition for prevention or treatment of an inflammatory disease according to any one of [15] to [17], which is characterized in that RANKL and/or M-CSF is administered before surgery, so as to prevent a postoperative inflammatory disease.

[19] The composition for prevention or treatment of an inflammatory disease according to any one of [15] to [18], in which the inflammatory disease is an infectious disease, an allergic disease, or an autoimmune disease.

[20] The composition for prevention or treatment of an inflammatory disease according to [19], in which the inflammatory disease is sepsis.

[21] An immunosuppressive agent, comprising RANKL and/or M-CSF as an active ingredient.

[22] The immunosuppressive agent according to [21], comprising RANKL and M-CSF as active ingredients.

[23] The immunosuppressive agent according to [22], in which the immunosuppressive agent is a combination preparation.

[24] The immunosuppressive agent according to [23], in which the immunosuppressive agent is a kit comprising a drug that contains RANKL and a drug that contains M-CSF.

72813-305

According to one aspect of the present invention, there is provided a method for detection of a bacterial infectious disease or sepsis with the use of RANKL (receptor activator of NF- κ B ligand) and/or OPG (osteoprotegerin) as a marker in a biological sample from a subject, comprising measuring RANKL and/or

5 OPG in the biological sample from the subject, and determining that the subject is affected with the bacterial infectious disease or sepsis when the concentration of soluble RANKL in the biological sample is lower than in a biological sample of a normal subject, or when the concentration of OPG in the biological sample is higher than in the biological sample of a normal subject.

10 According to another aspect of the present invention, there is provided a detection reagent for detection of a bacterial infectious disease or sepsis with the use of RANKL (receptor activator of NF- κ B ligand) and/or OPG (osteoprotegerin) as a marker, comprising means for measuring RANKL and/or OPG in a biological sample from a subject using an anti-RANKL antibody and/or anti-OPG antibody.

15 According to still another aspect of the present invention, there is provided a detection reagent for detection of a bacterial infectious disease or sepsis with the use of RANKL (receptor activator of NF- κ B ligand) and/or OPG (osteoprotegerin) as a marker, comprising an anti-RANKL antibody and/or an anti-OPG antibody.

20 According to yet another aspect of the present invention, there is provided a composition for prevention or treatment of an infectious disease, an allergic disease, or an autoimmune disease, comprising RANKL (receptor activator of NF- κ B ligand) and M-CSF (macrophage colony stimulating factor) as active ingredients, and a carrier, a diluent or an excipient.

25 According to a further aspect of the present invention, there is provided an immunosuppressive agent, comprising RANKL (receptor activator of NF- κ B ligand) and M-CSF (macrophage colony stimulating factor) as active ingredients, and a carrier, a diluent or an excipient.

72813-305

Effects of the Invention

When a subject is affected with an inflammatory disease such as an infectious disease, RANKL expression decreases and OPG expression increases. Therefore, an

inflammatory disease can be detected and diagnosed by measurement of the amount of RANKL or OPG. Particularly when the ratio of the amount of RANKL to the amount of OPG is used as an indicator, high-precision detection and diagnosis can be performed.

Furthermore, RANKL and/or M-CSF has an effect of suppressing inflammatory cytokine production by various macrophages. Moreover, an inflammatory disease can be prevented or treated with the use of RANKL and/or M-CSF.

Brief Description of the Drawings

Fig. 1 shows a lack of the induction of cytokine production due to soluble RANKL.

Fig. 2 shows RANKL-induced tolerance in macrophages based on inflammatory cytokine concentrations.

Fig. 3 shows RANKL-induced tolerance in macrophages based on inflammatory cytokine mRNA levels.

Fig. 4 shows RANKL-induced tolerance in macrophages based on the concentrations of TNF- α produced when macrophages were pretreated with soluble RANKL for given periods of time and then stimulated with LPS.

Fig. 5 shows RANKL-induced tolerance in macrophages based on the concentrations of TNF- α produced when peritoneal macrophages (PMs) and M-CSF-dependent spleen-derived macrophages (MDSMs) were pretreated with soluble RANKL for given periods of time and then stimulated with LPS.

Fig. 6 shows RANKL-induced tolerance with respect to various stimulations.

Fig. 7 shows the reversibility of RANKL-induced tolerance.

Fig. 8 shows attenuation of RANKL-induced tolerance by GM-CSF.

Fig. 9 shows changes in serum soluble RANKL and OPG concentrations in response to LPS injection.

Fig. 10 shows changes in serum soluble RANKL and OPG concentrations in

response to Salmonella infection.

Fig. 11 shows serum soluble RANKL and OPG concentrations in wild-type mice and mice lacking RANKL ($Tnfsf11^{-/-}$).

Fig. 12 shows serum cytokine concentrations in wild-type mice and mice lacking RANKL ($Tnfsf11^{-/-}$) into which LPS was injected intraperitoneally.

Fig. 13 shows serum soluble RANKL and OPG concentrations in wild-type mice and mice lacking OPG ($Tnfrsf11b^{-/-}$).

Fig. 14 shows serum cytokine concentrations in wild-type mice and mice lacking OPG ($Tnfrsf11b^{-/-}$), into which LPS was injected intraperitoneally.

Fig. 15 shows survival curves after intraperitoneal injection of a high dose of LPS into wild-type mice ($n = 10$) and $Tnfsf11^{-/-}$ mice ($n = 5$).

Fig. 16 shows that TLR4 expression is suppressed by treatment of macrophages with soluble RANKL.

Fig. 17 shows antigen presentation suppressed by soluble RANKL.

Fig. 18 shows that RANKL tolerance is c-Fos-independent.

Fig. 19 shows the nucleotide sequence of cDNA that encodes human-type RANKL residues 140 to 317 and the corresponding amino acid sequence.

Fig. 20 shows a restriction enzyme map of a vector containing a RANKL gene.

Fig. 21A shows the nucleotide sequence of a vector containing a RANKL gene (1/2).

Fig. 21B shows the nucleotide sequence of a vector containing the RANKL gene (2/2, continuation from Fig. 21A).

Fig. 22 shows a method for construction of a GST-RANKL vector.

Fig. 23 shows survival percentage when LPS was administered to the mice to which GST-RANKL and/or M-CSF had been administered.

Best Mode of Carrying Out the Invention

RANKL (Receptor activator of NF- κ B ligand) is a ligand of RANK (receptor activator of NF- κ B) that is a member of the TNF superfamily and is a type II transmembrane protein having an intracellular domain (the domain comprising amino acids 1 to 48 from the N terminus of RANK), a transmembrane domain, and an extracellular domain (JP Patent Publication (Kohyo) No. 2002-509430 and International Publication WO98/46644 pamphlet). In the extracellular domain, a domain comprising amino acid 152 (from the N terminus) and the following amino acids is a TNF ligand family homologous domain.

OPG (osteoprotegerin) has a structure analogous to that of RANK and can bind to RANKL.

When a subject is affected with an inflammatory disease, RANKL expression decreases, OPG expression increases, blood soluble RANKL concentration decreases, and OPG concentration increases.

The method of the present invention is a method for detection of an inflammatory disease, which comprises measuring RANKL and/or OPG in a biological sample collected from a subject and performing detection with the use of RANKL and/or OPG as a marker. RANKL to be measured in the method of the present invention is soluble RANKL (sRANKL) secreted in a biological sample that is a body fluid such as blood or membrane-type RANKL existing on cells in peripheral blood or the like.

Examples of a biological sample include blood, plasma, serum, tears, urine, amniotic fluids, synovial fluids, spinal fluids, cell extracts, tissue extracts, cells, and tissues. The effects of an inflammatory disease are often expressed throughout the body, so that blood, plasma, and serum are preferable among the above biological samples.

In the method of the present invention, the term “inflammatory disease” refers to a generic term of diseases with the presentation of inflammatory symptoms, including infectious diseases, allergy diseases, and autoimmune diseases, for example. Examples of such diseases include severely diseased trauma, burn, surgical invasion, acute pancreatitis,

peritonitis, malignant tumor, acute abdomen (abdominal disease with an acute abdominal pain as a predominant symptom, which requires emergency surgery), infectious diseases (particularly, nosocomial infections due to Gram-negative bacteria such as *Serratia*, *Pseudomonas aeruginosa*, *Acinetobacter*, *Citrobacter*, and *Enterobacter*), and a severe acute disease (namely, SIRS) requiring treatment in ICU, such as sepsis. Furthermore, allergy diseases such as contact hypersensitivity, allergic rhinitis, food allergy, and asthma are also diseases to be subjected to the method of the present invention. Further examples of the inflammatory disease include inflammatory skin diseases such as atopic dermatitis, contact dermatitis, photosensitive dermatitis, chronic dermatitis of fingers and toes, seborrheic dermatitis, nummular dermatitis, generalized exfoliative dermatitis, stasis dermatitis, local dermatitis due to abrasion, dermatitis medicamentosa, or psoriasis. Further examples of the inflammatory disease include autoimmune diseases such as rheumatoid arthritis, scleroderma, dermatomyositis, autoimmune vasculitis, mixed connective tissue disease, systemic erythematosus, idiopathic thrombocytopenic purpura, Crohn's disease, and human adjuvant disease.

Whether or not a subject is affected with the above inflammatory disease can be detected and diagnosed by the method of the present invention. Furthermore, the severity of the above inflammatory disease can be evaluated and determined. In particular, the severity of sepsis can be evaluated and determined.

A method for measuring RANKL and/or OPG is not limited. For example, RANKL and/or OPG can be measured by immunoassay using an anti-RANKL antibody and/or an anti-OPG antibody, such as Western blotting, EIA, RIA, an agglutination method, immunochromatography, or a flow cytometric method. When membrane-bound RANKL on cells in peripheral blood or the like is measured, a bound RANKL level (amount of RANKL) on cells is measured by a flow cytometric method. Measurement by flow cytometry can be performed using a flow cytometer such as a commercially available FACS. An anti-RANKL antibody and/or anti-OPG antibody

can be prepared by a known method. When measurement is performed using an antibody, an antibody to be used herein is labeled adequately with an enzyme such as alkaline phosphatase or a fluorescent dye. In addition, extracellular domains of soluble RANKL and membrane-type RANKL are subjected to measurement in the present invention, an anti-RANKL antibody preferred herein recognizes and binds to the extracellular domains of soluble RANKL and membrane-type RANKL. Soluble RANKL contains no intracellular domain, so that an anti-RANKL antibody to be used in the method of the present invention is an antibody capable of recognizing an extracellular domain other than the intracellular domains of RANKL and preferably recognizing an epitope that exists in a TNF ligand family homologous domain. Furthermore, a commercially available antibody can also be used. Furthermore, RANKL and/or OPG mRNA is detected and then the expression of RANKL and/or OPG may be detected. mRNA can be detected by Northern blotting, an RT-PCR method, a method using DNA chips (DNA microarray), or the like. At this time, a probe or primers comprising partial sequences complementary to the partial sequences of mRNA encoding RANKL and/or OPG are used for measuring specifically mRNA that encodes RANKL and/or OPG. The nucleotide sequences of RANKL and OPG are known. Probes or primers can be designed based on the known nucleotide sequence information. The number of the nucleotides of a primer or a probe ranges from 5 to 50, preferably 10 to 30, and further preferably 15 to 25. These methods can be performed by known methods.

When a RANKL concentration or amount in a sample collected from a subject is significantly lower than that of a normal subject or when an OPG concentration is significantly higher than that of a normal subject, the subject can be diagnosed as being affected with an inflammatory disease. Furthermore, it can be evaluated and determined that the lower the RANKL concentration or amount or the higher the OPG concentration, the severer the inflammatory disease such as sepsis.

Moreover, when the concentration ratio of soluble RANKL to OPG (soluble RANKL concentration : OPG concentration) in a sample collected from a subject is lower than that of a normal subject, the subject can be diagnosed as being affected with an inflammatory disease. Furthermore, it can be evaluated and determined that the lower the concentration ratio of soluble RANKL to OPG, the severer the inflammatory disease such as sepsis.

The expression of RANKL and/or OPG can fluctuate within several hours after the onset of an inflammatory disease. Hence, an inflammatory disease can be detected at an early phase according to the method of the present invention. Furthermore, several times of measurement of RANKL and/or OPG at appropriate time intervals enables more precise detection.

The present invention encompasses a reagent or a kit for detection of an inflammatory disease with the use of RANKL and/or OPG as a marker. The reagent or the kit comprises an anti-RANKL antibody and/or an anti-OPG antibody. When soluble RANKL and OPG are measured by ELISA or the like, an antibody may be labeled with an enzyme such as alkaline phosphatase or horseradish peroxidase. In addition, when membrane-bound RANKL is measured by a flow cytometric method, an antibody against RANKL may be labeled with a fluorescent dye.

The present invention further encompasses a marker for detection of an inflammatory disease, which comprises RANKL and/or OPG. The present invention further encompasses the use of RANKL and/or OPG as a marker for detection of an inflammatory disease.

The present invention further encompasses a composition (anti-inflammatory agent) or an immunosuppressive agent for treatment or prevention of an inflammatory disease, comprising RANKL and/or M-CSF as an active ingredient. When RANKL alone or a combination of RANKL and M-CSF is administered to a subject, inflammatory cytokine production by macrophages is suppressed in the subject, TLR4

level is suppressed, and the antigen-presenting ability of antigen-presenting cells of the subject is suppressed. Accordingly, RANKL and M-CSF can be used independently or in combination for treatment or prevention of inflammatory diseases. Furthermore, the immunity of a subject can be suppressed by the use of RANKL and M-CSF independently or in combination. In addition, RANKL-induced tolerance (RANKL tolerance) in macrophages is independent from c-Fos required for osteoclast differentiation. Thus, the effects of RANKL on macrophages differ from the “phenomenon of differentiation from macrophages” in the process of differentiation of macrophages into osteoclasts.

The term “inflammatory disease” which is a target of the composition for prevention or treatment of the present invention is a generic term for diseases with presentation of inflammatory symptoms, including infectious diseases, allergy diseases, and autoimmune diseases, for example. Examples of such diseases include severely diseased trauma, burn, surgical invasion, acute pancreatitis, peritonitis, malignant tumor, acute abdomen (abdominal disease with an acute abdominal pain as a predominant symptom, which requires emergency surgery), infectious diseases (particularly, nosocomial infections due to Gram-negative bacteria), and a severe acute disease (namely, SIRS) requiring treatment in ICU, such as sepsis. Furthermore, allergy diseases such as contact hypersensitivity, allergic rhinitis, food allergy, and asthma are also diseases to be subjected to the method of the present invention. Further examples of the inflammatory disease include inflammatory skin diseases such as atopic dermatitis, contact dermatitis, photosensitive dermatitis, chronic dermatitis of fingers and toes, seborrheic dermatitis, nummular dermatitis, generalized exfoliative dermatitis, stasis dermatitis, local dermatitis due to abrasion, dermatitis medicamentosa, or psoriasis. Further examples of the inflammatory disease include autoimmune diseases such as rheumatoid arthritis, scleroderma, dermatomyositis, autoimmune vasculitis, mixed connective tissue disease, systemic erythematosis, idiopathic thrombocytopenic purpura,

Crohn's disease, and human adjuvant disease.

Examples of RANKL that can be used for the composition for treatment or the immunosuppressive agent of the present invention include RANKL, soluble RANKL, a soluble RANKL derivative, a soluble RANKL analog, a soluble RANKL fusion protein, or a soluble RANKL mimic. The full-length nucleotide sequence and amino acid sequence of human-derived RANKL are shown in SEQ ID NO: 1 and 2, respectively. A soluble RANKL derivative or a soluble RANKL analog is a protein comprising a partial sequence of the amino acid sequence of RANKL, such as truncated RANKL. A protein having RANKL activity is also included herein. A soluble RANKL derivative preferably contains a TNF ligand family homologous domain that begins from amino acid 152 in the amino acid sequence of SEQ ID NO: 2. Examples of such a soluble RANKL derivative include a protein comprising the amino acid sequence ranging from amino acid 127 to amino acid 317, a protein comprising the amino acid sequence ranging from amino acid 140 to amino acid 317, or a protein comprising the amino acid sequence ranging from amino acid 159 to amino acid 317. Furthermore, examples of a soluble RANKL derivative or a soluble RANKL analog include a protein comprising an amino acid sequence that comprises a deletion, substitution, or addition of one or several amino acids with respect to the amino acid sequence represented by SEQ ID NO: 2 and having RANKL activity, and a protein comprising an amino acid sequence that comprises a deletion, substitution, or addition of one or several amino acids with respect to the amino acid sequence of a protein that comprises a partial sequence of the amino acid sequence of the above RANKL and having RANKL activity. Here, the term "one or several" refers to 1 to 9, preferably 1 to 5, and further preferably 1 or 2. The term "soluble RANKL fusion protein" refers to a fusion protein prepared by fusing another protein to a soluble RANKL protein, a soluble RANKL derivative, or a soluble RANKL analog. An example of such "another protein" is glutathione S-transferase (GST). The nucleotide sequence of DNA encoding a fusion protein prepared by fusing GST to a protein

comprising an amino acid sequence ranging from amino acid 127 to amino acid 317 in the amino acid sequence of RANKL and the amino acid sequence of the fusion protein are shown in SEQ ID NOS: 3 and 4, respectively. The nucleotide sequence of DNA encoding a fusion protein prepared by fusing GST to a protein comprising an amino acid sequence ranging from amino acid 140 to amino acid 317 in the amino acid sequence of RANKL and the amino acid sequence of the fusion protein are shown in SEQ ID NOS: 5 and 6, respectively. Furthermore, the nucleotide sequence of DNA encoding a fusion protein prepared by fusing GST to a protein comprising an amino acid sequence ranging from amino acid 159 to amino acid 317 in the amino acid sequence of RANKL and the amino acid sequence of the fusion protein are shown in SEQ ID NOS: 7 and 8, respectively. The soluble RANKL mimic is a compound having a structure analogous to the conformation of RANKL and having RANKL activity. Such RANKL, soluble RANKL, soluble RANKL derivative, soluble RANKL analog, and soluble RANKL fusion protein can be prepared as recombinant proteins by gene-engineering techniques.

Examples of M-CSF to be used for the composition for prevention or treatment or the immunosuppressive agent of the present invention include, similarly to examples of RANKL, M-CSF, an M-CSF derivative, an M-CSF analog, an M-CSF fusion protein, and an M-CSF mimic. Such M-CSF, M-CSF derivative, M-CSF analog, and M-CSF fusion protein can be prepared as recombinant proteins by gene-engineering techniques. Furthermore, a commercially available M-CSF preparation can also be used. An example of such M-CSF is Leukoprol (Trademark, general name: mirimostim).

RANKL alone may be administered to a subject or M-CSF alone may also be administered to a subject for prevention or treatment of an inflammatory disease or immunosuppression. Preferably, both RANKL and M-CSF are administered. When both RANKL and M-CSF are administered, the mixture of the two, that is, a combination preparation prepared by mixing the two can be administered simultaneously. Furthermore, a composition containing RANKL and a composition containing M-CSF

are separately formulated, and then the two preparations can be mixed when used and then administered. Furthermore, the preparations may be administered separately in turn. Preferably, both RANKL and M-CSF are administered simultaneously. The composition for prevention or treatment or the immunosuppressive agent of the present invention is also a kit comprising a drug containing RANKL and a drug containing M-CSF for administration of RANKL and M-CSF separately.

Moreover, when the composition for prevention or treatment of an inflammatory disease of the present invention is used for treatment, the composition is administered to a patient affected with an inflammatory disease. Furthermore, when the composition is used for prevention, the composition is administered to a patient suspected of being affected with an inflammatory disease. For example, the composition is administered to a patient affected with a severe infectious disease who may be suspected of developing sepsis or SIRS. Furthermore, for prevention of postoperative infection, the composition of the present invention may be administered before invasive surgery. The immunosuppressive agent of the present invention comprising RANKL and/or M-CSF as an active ingredient is administered to a patient when a tissue or an organ is transplanted in the patient. The immunosuppressive agent of the present invention can suppress graft rejection associated with cell or organ and/or tissue transplantation and graft-versus-host disease.

The composition for prevention or treatment of an inflammatory disease or the immunosuppressive agent of the present invention can be administered in various forms. For example, the composition can be orally administered in the form of tablets, capsules, fine granules, powders, syrups, or the like or can also be parenterally administered in the form of injections, drops, suppositories, sprays, eye drops, intranasal agents, and adhesive preparations, or the like.

The composition for prevention or treatment of an inflammatory disease or the immunosuppressive agent of the present invention contains a carrier, a diluent, and an

excipient, which are generally used in the pharmaceutical field. For example, as a carrier and an excipient for tablets, lactose, magnesium stearate, and the like are used. As an aqueous solution for injection, a physiological saline solution, an isotonic solution containing glucose or other adjunctive agents, or the like is used. These examples may also be used in combination with an appropriate solubilizing agent such as alcohol, polyalcohol such as propylene glycol, a nonionic surfactant, and the like. As an oily liquid, sesame oil, soybean oil, or the like is used. As a solubilizing agent, benzyl benzoate, benzylalcohol, or the like may also be used in combination.

The dose is varied depending on symptoms, age, body weights, and the like. The dose in the case of oral administration ranges from approximately 0.001 mg to 1000 mg per day, and administration may be performed once or in divided doses. Furthermore, the dose in the case of parenteral administration ranges from 0.001 mg to 1000 mg per administration, and administration is performed by intravenous injection, intraperitoneal injection, subcutaneous injection, or intramuscular injection or using a suppository, an eye drop, or the like. When RANKL and M-CSF are used in combination, the ratio of the dose of RANKL to the dose of M-CSF is not limited. RANKL and M-CSF may be administered in the same amounts, or the amount of either soluble RANKL or M-CSF to be administered may be greater than the other.

The present invention further encompasses a method for prevention or treatment of an infectious disease or an immunosuppression method, comprising administering soluble RANKL and/or M-CSF to a patient who needs prevention or treatment.

The present invention further encompasses the use of soluble RANKL and/or M-CSF for production of a composition for prevention or treatment of an infectious disease or the use of the same for production of an immunosuppressive agent.

The present invention further encompasses soluble RANKL and/or M-CSF to be used for treatment of an infectious disease or soluble RANKL and/or M-CSF to be used for immunosuppression.

Examples

The present invention is hereafter described in greater detail with reference to the following examples, although the present invention is not limited thereto.

The following materials and methods are used in the Examples.

Mice

Six to 10-week-old C57BL/6J mice were purchased from Oriental Yeast Co., Ltd. Homozygous mice lacking OPG and control heterozygous mice with a C57BL/6J background were purchased from Clea Japan. Mice lacking RANKL and mice lacking TLR4 with a C57BL/6J background were bred and maintained under specific pathogen-free conditions (SPF). A powder diet was provided to mice lacking RANKL. All experiments were performed in accordance with guidelines for animal use at the Keio University School of Medicine or Oriental Yeast Co., Ltd.

M-CSF-dependent macrophage

To generate M-CSF-dependent bone marrow-derived macrophages (MDBMs), bone marrow cells were harvested by flushing tibias and femurs with Dulbecco's modified Eagle's medium (DMEM) containing 10% fetal calf serum (FCS) and antibiotics. After passage through a cell strainer, bone marrow cells were cultured overnight. Non-adherent cells were harvested and cultured in the presence of 10 ng/ml M-CSF. After 3 to 4 days, cells that had adhered to the wells were harvested using a cell scraper and then seeded as M-CSF-dependent bone marrow-derived macrophages at a concentration of 1×10^5 /well in a 24-well plate (Falcon). M-CSF-dependent spleen-derived macrophages (MDSMs) were generated from splenocytes by a method similar to the above method. All macrophages were cultured in the presence of 10 ng/ml M-CSF in all experiments.

Peritoneal macrophages

Peritoneal cells were harvested by flushing the peritoneal cavity of mice with complete medium (DMEM containing 10% FCS and antibiotics). The thus harvested cells were seeded at a concentration of 1×10^5 /well in a 24-well plate (Falcon). Cells were cultured for 6 hours, the plate was washed with PBS to remove non-adherent cells, and remaining cells were incubated in fresh medium. The thus obtained adherent cells were used as peritoneal macrophages.

In vitro tolerance experiments

Macrophages were pretreated with different concentrations of soluble RANKL (< 0.10 endotoxin units/mg, R&D) or LPS (also referred to as lipopolysaccharide or endotoxin; LPS used in the Examples is S. Minnesota Re595, Sigma) for given periods of time. Cultured cells were subsequently washed twice with phosphate buffered saline (PBS) and stimulated with LPS, flagellin derived from *Salmonella muenchen* (Calbiochem), CpG oligonucleotide (5'-TCCATgACgTTCCTgATgCT-3'; SEQ ID NO: 12), or control GpC oligonucleotides (5'-TCCATgAgCTTCCTgATgCT-3', Proligo; SEQ ID NO: 13) as indicated in the description. In some experiments, 500 U/ml GM-CSF (Pepro Tec) was added 3 hours before stimulation of cells with LPS.

Mouse LPS administration

LPS (S. Minnesota Re595, Sigma) was administered intraperitoneally. LPS (*E. coli* O55: B5, Sigma) was used in the Example as shown in Fig. 23. Blood was collected by heart puncture at given time points. Blood was allowed to clot for 1 hour and then centrifuged at 15000 rpm at 24°C for 20 minutes. The serum was stored at -80°C until cytokine assays.

Bacterial strain and infection experiment

72813-305

For an infection experiment, an overnight standing culture of *Salmonella enterica* serovar Typhimurium χ 3306 strain (hereinafter, *Salmonella*) in Luria-Bartani broth (LB medium) was diluted and shaken, and mid-log phase bacteria were then collected by centrifugation. *Salmonella* was washed with PBS, diluted with Hanks' salt solution, and used to infect macrophages at a multiplicity of infection (MOI) of 10. After incubation at 37°C for 1 hour, macrophages were washed with PBS to remove extracellular *Salmonella* and then incubated in complete medium containing 25 μ g/ml gentamycin. After 3 hours, culture supernatants were harvested for cytokine assays. For oral infection with *Salmonella*, mice were subjected to fasting with no water and feed for 12 hours before infection, and then 3.3×10^7 CFU/g body weight of *Salmonella* was administered orally. Four days later, blood was collected by heart puncture.

Enzyme-linked immunosorbent assay (ELISA)

TNF- α , IL-6, and IL-12 (p40) concentrations in macrophage culture supernatants were measured using ELISA sets (BD PharMingen). Soluble RANKL and OPG concentrations in mouse serum were measured using ELISA kits (R&D).

PT-PCR analysis

mRNA was prepared by collecting macrophages and homogenizing the macrophages in Isogen (Nippon gene). cDNA was synthesized using the Enhanced Avian HS RT-PCR kit (Sigma-Aldrich). Quantitative PCR was performed using an ABI PRISM 7000 apparatus TaqMan[™] Assay-on-demand (Applied Biosystems) and IL-6, TNF- α , IL-12 (p40), and Gapdh primers.

Statistical analysis

Data are expressed as means $\pm$ SD (standard deviation). All data excluding those of the Example, the results of which are shown in Fig. 23, were analyzed by

significant difference tests using the Student's t-test. Only in the Example, the results of which are shown in Fig. 23, significant difference tests were performed using a generalized Wilcoxon test.

The following results were obtained.

(1) Induction of RANKL tolerance in macrophages stimulated with bacterial components

First, M-CSF-dependent bone marrow-derived macrophages (MDBMs) were stimulated with soluble RANKL or LPS and then inflammatory cytokine production was measured (Fig. 1A to C). Fig. 1A to C show the lack of the induction of cytokine production because of soluble RANKL. MDBMs were stimulated with LPS or soluble RANKL with a concentration shown in Fig. 1 for 24 hours. Protein concentrations of inflammatory cytokines in culture supernatants were measured by ELISA. Bars in Fig. 1 represent means $\pm$ SD ($n = 3$, culture well). As shown in Fig. 1A to C, it was revealed that while LPS significantly induced the production of cytokines such as TNF- α , IL-6, and IL-12 (p40), soluble RANKL with a concentration as high as 100 ng/ml did not induce detectable levels of cytokine production. Therefore, unlike LPS, soluble RANKL cannot induce inflammatory cytokines.

Next, MDBMs were pretreated for 24 hours with soluble RANKL by increasing the concentration of soluble RANKL in steps and then stimulated with LPS for 6 hours. The concentrations of TNF- α , IL-6, and IL-12 (p40) in the supernatants were measured by ELISA. As a result, it was revealed that pretreatment of soluble RANKL suppresses cytokine production resulting from subsequent stimulation with LPS in a soluble RANKL concentration-dependent manner (Fig. 2A to C). Fig. 2A to C show the protein concentration of each inflammatory cytokine, showing that RANKL-induced tolerance was induced in macrophages. MDBMs were pretreated with soluble RANKL for 24 hours (1°) and then stimulated with 100 ng/ml LPS for 6 hours (2°). As shown in Fig.

2A to C, such induced tolerance was also observed at a low concentration (as low as 1 ng/ml) of soluble RANKL.

The mRNA levels of TNF- α , IL-6, and IL-12 (p40) were measured with time over 6 hours after stimulation with LPS. Compared with macrophages not pretreated with soluble RANKL, macrophages pretreated with soluble RANKL showed significantly suppressed induction of cytokine mRNAs upon LPS stimulation (Fig. 3A to C). Fig. 3A to C show the mRNA level of each inflammatory cytokine, showing that RANKL-induced tolerance was induced in macrophages. MDBMs were pretreated with medium alone (open diamonds) or 10 ng/ml soluble RANKL (close diamonds) for 24 hours and then stimulated with 100 ng/ml LPS for 6 hours. Cells were harvested at each time point as in Fig. 3. Cytokine mRNA levels were measured by quantitative PCR. Values are normalized to Gapdh.

Next, the duration of pretreatment with soluble RANKL was shortened to 24 hours, 12 hours, and 6 hours. MDBMs were pretreated with 1 ng/ml soluble RANKL for given periods of time as in Fig. 4 (1°) and then stimulated with LPS (2°). As a result, it was revealed that even as short as 6 hours of pretreatment significantly suppressed the induction of TNF- α production in response to stimulation with LPS (Fig. 4).

To examine whether or not RANKL-induced tolerance takes place in macrophages other than MDBMs, an experiment was then conducted using peritoneal macrophages (PMs) and M-CSF-dependent spleen-derived macrophages (MDSMs). Peritoneal macrophages (PMs) and M-CSF-dependent spleen-derived macrophages (MDSMs) were pretreated with 50 ng/ml soluble RANKL for 24 hours (1°) and then stimulated with LPS (2°). As a result, the induction of TNF- α production in response to stimulation with LPS was suppressed in these macrophages when the macrophages had been pretreated with soluble RANKL (Fig. 5).

Finally, MDBMs were pretreated with soluble RANKL for 24 hours and then

stimulated with flagellin, CpG oligonucleotide, and Salmonella. MDBMs were pretreated with 10 ng/ml soluble RANKL for 24 hours (1°) and then stimulated with 1×10^{-11} M flagellin or 3 nM CpG DNA for 6 hours or with Salmonella for 3 hours (2°). Cytokines in the culture supernatants were measured by ELISA. As a result, it was revealed that pretreatment with soluble RANKL suppressed the induction of TNF- α production in response to stimulation with the bacterial components or Salmonella (Fig. 6A to C). Bars in Fig. 6 represent means $\pm$ SD (n = 3, culture well). “*, P<0.05; **, P<0.01” represent the results compared with open bars. These results suggest that soluble RANKL lowers the responsiveness of macrophages to LPS or other bacterial components.

(2) Attenuation of RANKL-induced tolerance by soluble RANKL removal or GM-CSF treatment

To examine whether or not RANKL-induced tolerance is reversible, MDBMs were treated with soluble RANKL for 24 hours and then cultured in soluble-RANKL-free medium for another 24 hours. MDBMs were treated with medium alone (Med) or 10 ng/ml soluble RANKL for 24 hours (Day 1), treated with medium alone (Med) or 10 ng/ml soluble RANKL for another 24 hours (Day 2), and then stimulated with 100 ng/ml LPS for 6 hours. Culture supernatants (n = 3) were harvested for measurement of cytokine concentrations by ELISA. Compared with a control group, production of TNF- α , IL-6, and IL-12 (p40) was sufficiently or at least partially restored, demonstrating that RANKL-induced tolerance is reversible (Fig. 7A to C). Bars in Fig. 7 represent means $\pm$ SD. “*, P<0.01” represent the results compared with close bars.

GM-CSF is known to inhibit RANKL/RANK signaling. Hence, the effects of GM-CSF on RANKL-induced tolerance were examined. MDSMs were pretreated with soluble RANKL for 24 hours and then treated with soluble RANKL-free GM-CSF-containing medium for 3 hours. Subsequently, cells were stimulated with

LPS and then TNF- α concentrations were measured. Specifically, MDBMs were treated with 10 ng/ml soluble RANKL for 24 hours (1°), stimulated with 500 U/ml GM-CSF for 3 hours (2°), and then stimulated with 100 ng/ml LPS for 6 hours (3°). The results are shown in Fig. 8. TNF- α concentrations ($n = 3$) in the culture supernatants were measured by ELISA. Bars in Fig. 8 represent means $\pm$ SD. *, $P < 0.01$. Data representative among three experiments are shown. As shown in Fig. 8, although GM-CSF itself did not induce TNF- α production, brief treatment with GM-CSF significantly increased TNF- α production in macrophages pretreated with soluble RANKL. These results suggest that GM-CSF attenuates RANKL-induced tolerance (Fig. 8). Taken together, it was demonstrated by the Example that short treatment with GM-CSF can restore the responsiveness of macrophages to LPS, as in the case of soluble RANKL removal.

(3) Dynamic shift of serum soluble RANKL and OPG levels due to LPS administration and bacterial infection

To compare physiological and pathological soluble RANKL concentrations in serum, LPS was injected intraperitoneally into mice and then serum soluble RANKL and OPG concentrations were measured. LPS was injected intraperitoneally into C57BL/6J mice ($n = 24$) (1 μ g/g body weight). Blood was collected at each time point as in Fig. 9 ($n = 3$, mouse/point). Serum soluble RANKL and OPG concentrations were measured by ELISA. The serum soluble RANKL concentration was approximately 150 pg/ml and OPG concentration was approximately 2000 pg/ml prior to LPS injection. The results are shown in Fig. 9A and B. Bars in Fig. 9 represent means $\pm$ SD. “*, $P < 0.05$; **, $P < 0.01$ ” show the results compared with that of 0h. Surprisingly, soluble RANKL concentration dramatically fell at 6 hours after LPS injection, while OPG concentration was up-regulated on hour 6 and later. Furthermore, C57BL/6J mice ($n = 6$) were orally infected with 3.3×10^7 CFU/g body weight of *Salmonella* (infection). Control mice were

caused to drink PBS (control). After 4 days, blood was collected and then serum soluble RANKL and OPG concentrations were measured by ELISA. The results are shown in Fig. 10A and B. As shown in Fig. 10, down-regulation of serum soluble RANKL and up-regulation of OPG were also observed on day 4 after oral infection with *Salmonella*. Bars in Fig. 10 represent means $\pm$ SD ($n = 3$). *, $P < 0.05$; **, $P < 0.01$. These results demonstrate that serum soluble RANKL and OPG levels are dynamically regulated in response to LPS and bacterial infection.

(4) Abnormal cytokine production in mice lacking RANKL and mice lacking OPG

To examine the effects of physiological serum soluble RANKL on LPS-induced cytokine production, *Tnfsf11*^{-/-} mice lacking RANKL were analyzed. Fig. 11A and B show serum soluble RANKL and OPG concentrations in wild-type mice and mice lacking RANKL (*Tnfsf11*^{-/-}), as measured by ELISA ($n = 4$ for each genotype). Bars in Fig. 11 represent means $\pm$ SD. “*, $P < 0.05$; **, $P < 0.01$ ” show the results compared with that of the control. As predicted, serum soluble RANKL was not detectable in *Tnfsf11*^{-/-} mice, but OPG levels were slightly higher in *Tnfsf11*^{-/-} mice than in wild-type mice.

Furthermore, LPS (2 μ g/g body weight) was injected intraperitoneally. Ninety minutes later, blood of wild-type mice and *Tnfsf11*^{-/-} mice were collected. Serum cytokines were measured by ELISA. After LPS injection, significantly elevated TNF- α production and IL-6 production were observed in *Tnfsf11*^{-/-} mice (Fig. 12A to C). Bars in Fig. 12 represent means $\pm$ SD. “*, $P < 0.05$; **, $P < 0.01$ ” show the results compared with that of the control. These results are consistent with the notion that the lack of RANKL-induced tolerance potentiates production of inflammatory cytokines in *Tnfsf11*^{-/-} mice.

To further examine the role of RANKL-induced tolerance in mice, *Tnfsf11b*^{-/-} mice lacking OPG were analyzed. Fig. 13A and B show serum soluble RANKL and

OPG concentrations in wild-type mice and mice lacking OPG ($Tnfrsf11b^{-/-}$), as measured by ELISA ($n = 5$ for each genotype). Bars in Fig. 13 represent means $\pm$ SD. “*, $P<0.05$; **, $P<0.01$ ” show the results compared with that of the control. Compared with control heterozygous mice lacking OPG, physiological serum soluble RANKL concentration was approximately 10 times higher in $Tnfrsf11b^{-/-}$ mice. Therefore, it can be said that mice lacking OPG are always exposed to high soluble RANKL concentrations.

Furthermore, LPS (2 μ g/g body weight) was injected intraperitoneally. Ninety (90) minutes later, blood was collected from wild-type mice and $Tnfrsf11b^{-/-}$ mice and then serum cytokines were measured by ELISA. The results are shown in Fig. 14A to C. Bars in Fig. 14 represent means $\pm$ SD. “*, $P<0.05$; **, $P<0.01$ ” show the results compared with that of the control. It was revealed that after LPS injection, IL-6 production significantly decreased in $Tnfrsf11b^{-/-}$ mice. Therefore, it was demonstrated that chronic exposure to high soluble RANKL concentrations suppresses inflammatory cytokine production in mice lacking OPG.

(5) Hypersensitivity of mice lacking RANKL to LPS

To analyze the effects of abnormal inflammatory cytokine production in mice lacking RANKL, we intraperitoneally injected a high concentration of LPS into wild-type mice and $Tnfrsf11^{-/-}$ mice and then compared the resulting survival percentages. A high dose of LPS (130 μ g/g body weight) was intraperitoneally injected into 6-week-old wild-type mice ($n = 10$) and $Tnfrsf11^{-/-}$ mice ($n = 5$), and then survival curves were generated. As a result, while 90% of wild-type mice ($n = 10$, open square) survived at 24 hours after injection, all $Tnfrsf11^{-/-}$ mice ($n = 5$, close square) died within 24 hours (Fig. 15). $Tnfrsf11^{-/-}$ mice were hypersensitive to LPS. These results suggest that physiological serum soluble RANKL functions to protect mice from endotoxin shock.

(6) Decreased TLR4 by soluble RANKL

When macrophages were treated with soluble RANKL for 24 hours, the mRNA level of TLR4 was significantly suppressed. Even when macrophages were treated with soluble RANKL, stimulated with LPS, and then the mRNA level of TLR4 at this time was observed with time, the same tendency was observed (Fig. 16A). Bars in Fig. 16 represent means $\pm$ SD. Moreover, it was revealed by flow cytometry analysis that 24 hours of treatment of macrophages with soluble RANKL suppresses the expression of TLR4-MD2 complex on cell surfaces (Fig. 16B). Since TLR4 is an LPS receptor, it was suggested that such a decreased TLR4 level plays a role in the mechanism of RANKL tolerance.

(7) Suppression of antigen presentation by soluble RANKL

It was revealed by flow cytometry analysis that 24 hours of treatment of macrophages with soluble RANKL results in significant decreases in the expression of MHCII, CD80, and CD86 on the surfaces (Fig. 17, continuous lines represent the results of the group treated with soluble RANKL and broken lines (gray) represent the results of the control group). MHCII is a molecule for presenting foreign antigens to lymphocytes and co-stimulatory molecules such as CD80 and CD86 are considered to be essential at this time.

Therefore, decreased expression levels of these molecules suggest that soluble RANKL is capable of suppressing antigen presentation by macrophages.

(8) c-Fos-independent RANKL tolerance

Transduction of RANKL/RANK signal in osteoclast differentiation requires the c-Fos transcription factor. Mice lacking c-Fos are unable to produce osteoclasts. To examine whether or not c-Fos is required for RANKL tolerance to occur, macrophages

derived from mice lacking c-Fos were analyzed. Macrophages derived from mice lacking c-Fos were pretreated with 1 ng/ml LPS for 24 hours and then stimulated with 100 ng/ml LPS to observe LPS tolerance. It was revealed that LPS tolerance occurred similarly to the case of the wild-type mice (Fig. 18 A and B). Moreover, macrophages derived from the same were pretreated with 10 ng/ml soluble RANKL for 24 hours and then stimulated with 100 ng/ml LPS to observe RANKL tolerance. Thus, it was also revealed that RANKL tolerance occurred similarly to the case of the wild-type mice (Fig. 18 C and D). Bars in Fig. 18 represent means $\pm$ SD. Therefore, it can be concluded that LPS tolerance or RANKL tolerance is c-Fos-independent. That is, RANKL tolerance should not be considered to be only the “phenomenon of macrophage differentiation” in the process during which macrophages differentiate into multinucleated osteoclasts.

(9) Mouse acute toxicity test

Mice used herein were 7- to 8-week-old C57BL/6N (female) mice.

LPS used herein was Lipopolysaccharides from *Escherichia coli* O55:B5 (Sigma). Sterile water (1.0 ml) was added to 10 mg each of LPS for dissolution and then the solution was used. M-CSF used herein was Leukoprol (KYOWA HAKKO KOGYO Co., Ltd.). PBS (1.0 ml) was added to 50 μ g each of M-CSF for dissolution and then the solution was used.

Preparation of GST-RANKL

Sal I, *Not* I site was added to cDNA encoding human-type RANKL residues 140 to 317 by PCR. With the use of these endonucleases, the sequence was cloned downstream of Glutathione S-transferase of pGEX-4T-2 (GE healthcare; Genbank Accession Number U13854). The nucleotide sequence of cDNA encoding human-type RANKL residues 140 to 317 and the corresponding amino acid sequence are shown in Fig. 19. Moreover, the restriction enzyme map of a vector containing the RANKL gene

72813-305

is shown in Fig. 20. Furthermore, the nucleotide sequence of the vector is shown in Fig. 21A and 21B. The nucleotide sequence in Fig. 21 B is continued from the nucleotide sequence in Fig. 21 A. After induction of IPTG (final concentration: 0.5 mM)-mediated protein expression in BL21 (DE3) *Escherichia coli* (Invitrogen), microbes were suspended in an extraction buffer (50 mM Tris-HCl, pH 8.0, 100 mM NaCl, 1 mM EDTA, 1 mM DTT, and 1% (v/v) TritonX-100[™]) and then disrupted at 4°C using an ultrasonicator. After centrifugation at 18000×g for 15 minutes, the supernatants were collected and then subjected to a Glutathione Sepharose (Trademark) column. Subsequently, the resultants were washed with a buffer for washing (50 mM Tris-HCl, pH 8.0, 100 mM NaCl, 1 mM DTT, and 0.1% (v/v) TritonX-100). Subsequently, elution was performed with a Glutathione solution (20 mM reduced glutathione, 50 mM Tris-HCl, and pH8.0). The molecular weight and the purity of GST-RANKL purified by SDS-PAGE were confirmed, followed by filtration. The molecular weight was 47.0 kDa and the purity was 95% or higher. Furthermore, endotoxin concentrations were measured by limulus amebocyte lysate assay, so that the concentrations were confirmed to be less than 1 EU/μg.

A method for constructing a GST-RANKL expression vector is shown in Fig. 22.

Test of administration of LPS, RANKL, and M-CSF

Ten (10) μg of GST-RANKL, 2 μg of M-CSF, 2 μg of M-CSF + 10 μg of GST-RANKL, and PBS as a control were separately administered intraperitoneally to C57BL/6N mice (9 to 10 mice per group). After 24 hours, LPS (2.5 mg/mouse) was administered intraperitoneally. Subsequent survival was observed until hour 144 after the administration.

The results are shown in Fig. 23. As shown in Fig. 23, survival% was significantly high ($P < 0.03$) when RANKL and M-CSF had been administered.

72813-305

Sequence Listing Free Text

SEQ ID NOS: 3 and 4: GST-RANKL (aa127-317)

SEQ ID NOS: 5 and 6: GST-RANKL (aa140-317)

SEQ ID NOS: 7 and 8: GST-RANKL (aa159-317)

SEQ ID NOS: 9 to 13: synthesis

SEQUENCE LISTING IN ELECTRONIC FORM

In accordance with Section 111(1) of the Patent Rules, this description contains a sequence listing in electronic form in ASCII text format (file: 72813-305 Seq 28-10-08 v1.txt).

A copy of the sequence listing in electronic form is available from the Canadian Intellectual Property Office.

The sequences in the sequence listing in electronic form are reproduced in the following table.

SEQUENCE TABLE

<110> KEIO UNIVERSITY; ORIENTAL YEAST Co., Ltd.

<120> A method of detecting inflammatory diseases and a composition for preventing or treating inflammatory diseases

<130> PH-2808-PCT

<160> 13

<170> PatentIn Ver. 2.1

<210> 1

<211> 2201

<212> DNA

<213> Homo sapiens

<220>

<221> CDS

<222> (129)..(1082)

<400> 1

ggccaaagcc gggctccaag tcggcgcccc acgtcgaggc tccgccgcag cctccggagt 60
tggccgcaga caagaagggg agggagcggg agagggagga gagctccgaa gcgagagggc 120

cgagcgcc atg cgc cgc gcc agc aga gac tac acc aag tac ctg cgt ggc 170
Met Arg Arg Ala Ser Arg Asp Tyr Thr Lys Tyr Leu Arg Gly
1 5 10

tcg gag gag atg ggc ggc ggc ccc gga gcc ccg cac gag ggc ccc ctg 218
Ser Glu Glu Met Gly Gly Gly Pro Gly Ala Pro His Glu Gly Pro Leu
15 20 25 30

cac gcc ccg ccg ccg cct gcg ccg cac cag ccc ccc gcc gcc tcc cgc 266
His Ala Pro Pro Pro Pro Ala Pro His Gln Pro Pro Ala Ala Ser Arg
35 40 45

tcc atg ttc gtg gcc ctc ctg ggg ctg ggg ctg ggc cag gtt gtc tgc 314
Ser Met Phe Val Ala Leu Leu Gly Leu Gly Leu Gly Gln Val Val Cys
50 55 60

agc gtc gcc ctg ttc ttc tat ttc aga gcg cag atg gat cct aat aga 362
Ser Val Ala Leu Phe Phe Tyr Phe Arg Ala Gln Met Asp Pro Asn Arg
65 70 75

ata tca gaa gat ggc act cac tgc att tat aga att ttg aga ctc cat	410
Ile Ser Glu Asp Gly Thr His Cys Ile Tyr Arg Ile Leu Arg Leu His	
80 85 90	
gaa aat gca gat ttt caa gac aca act ctg gag agt caa gat aca aaa	458
Glu Asn Ala Asp Phe Gln Asp Thr Thr Leu Glu Ser Gln Asp Thr Lys	
95 100 105 110	
tta ata cct gat tca tgt agg aga att aaa cag gcc ttt caa gga gct	506
Leu Ile Pro Asp Ser Cys Arg Arg Ile Lys Gln Ala Phe Gln Gly Ala	
115 120 125	
gtg caa aag gaa tta caa cat atc gtt gga tca cag cac atc aga gca	554
Val Gln Lys Glu Leu Gln His Ile Val Gly Ser Gln His Ile Arg Ala	
130 135 140	
gag aaa gcg atg gtg gat ggc tca tgg tta gat ctg gcc aag agg agc	602
Glu Lys Ala Met Val Asp Gly Ser Trp Leu Asp Leu Ala Lys Arg Ser	
145 150 155	
aag ctt gaa gct cag cct ttt gct cat ctc act att aat gcc acc gac	650
Lys Leu Glu Ala Gln Pro Phe Ala His Leu Thr Ile Asn Ala Thr Asp	
160 165 170	
atc cca tct ggt tcc cat aaa gtg agt ctg tcc tct tgg tac cat gat	698
Ile Pro Ser Gly Ser His Lys Val Ser Leu Ser Ser Trp Tyr His Asp	
175 180 185 190	
cgg ggt tgg gcc aag atc tcc aac atg act ttt agc aat gga aaa cta	746
Arg Gly Trp Ala Lys Ile Ser Asn Met Thr Phe Ser Asn Gly Lys Leu	
195 200 205	
ata gtt aat cag gat ggc ttt tat tac ctg tat gcc aac att tgc ttt	794
Ile Val Asn Gln Asp Gly Phe Tyr Tyr Leu Tyr Ala Asn Ile Cys Phe	
210 215 220	
cga cat cat gaa act tca gga gac cta gct aca gag tat ctt caa cta	842
Arg His His Glu Thr Ser Gly Asp Leu Ala Thr Glu Tyr Leu Gln Leu	
225 230 235	
atg gtg tac gtc act aaa acc agc atc aaa atc cca agt tct cat acc	890
Met Val Tyr Val Thr Lys Thr Ser Ile Lys Ile Pro Ser Ser His Thr	
240 245 250	
ctg atg aaa gga gga agc acc aag tat tgg tca ggg aat tct gaa ttc	938
Leu Met Lys Gly Gly Ser Thr Lys Tyr Trp Ser Gly Asn Ser Glu Phe	
255 260 265 270	
cat ttt tat tcc ata aac gtt ggt gga ttt ttt aag tta cgg tct gga	986
His Phe Tyr Ser Ile Asn Val Gly Gly Phe Phe Lys Leu Arg Ser Gly	
275 280 285	
gag gaa atc agc atc gag gtc tcc aac ccc tcc tta ctg gat ccg gat	1034
Glu Glu Ile Ser Ile Glu Val Ser Asn Pro Ser Leu Leu Asp Pro Asp	
290 295 300	
cag gat gca aca tac ttt ggg gct ttt aaa gtt cga gat ata gat tga	1082
Gln Asp Ala Thr Tyr Phe Gly Ala Phe Lys Val Arg Asp Ile Asp	
305 310 315	
gccccagttt ttggagtgtt atgtatttcc tggatgtttg gaaacatttt ttaaaacaag	1142
ccaagaaaga tgtatatagg tgtgtgagac tactaagagg catggcccca acggtacacg	1202
actcagtatc catgctcttg accttgtaga gaacacgcgt atttacctgc cagtgggaga	1262
tgtagactc atggtgtgtt acacaatggt ttttaaattt tgtaatgaat tcctagaatt	1322

```

aaaccagatt ggagcaatta cgggttgacc ttatgagaaa ctgcatgtgg gctatgggag 1382
gggttggtcc ctggtcatgt gccccttcgc agctgaagtg gagaggggtgt catctagcgc 1442
aattgaagga tcatctgaag gggcaaattc ttttgaattg ttacatcatg ctggaacctg 1502
caaaaaatac tttttctaata gaggagagaa aatatatgta tttttatata atatctaaag 1562
ttatatttca gatgtaatgt tttctttgca aagtattgta aattatatatt gtgctatagt 1622
atttgattca aaatatttaa aaatgtcttg ctgttgacat atttaaatgtt ttaaattgtac 1682
agacatatatt aactggtgca ctttgtaaata tccctgggga aaacttgcag ctaaggaggg 1742
gaaaaaaatg ttgtttccta atatcaaata cagtatatatt cttcgttctt ttttaagttaa 1802
tagatttttt cagacttgtc aagcctgtgc aaaaaaatta aaatggatgc cttgaataat 1862
aagcaggatg ttggccacca ggtgcctttc aaatttagaa actaattgac tttagaaagc 1922
tgacattgcc aaaaaggata cataatgggc cactgaaatt tgtcaagagt agttatataa 1982
ttgttgaaca ggtgtttttc cacaagtgcc gcaaattgta cctttttttt tttttcaaaa 2042
tagaaaagtt attagtgggt tatcagcaaa aaagtccaat ttttaatttag taaatgttat 2102
tttatactgt acaataaaaa cattgccttt gaatgttaat tttttggtac aaaaataaat 2162
ttatatgaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 2201

```

```

<210> 2
<211> 317
<212> PRT
<213> Homo sapiens

```

```

<400> 2
Met Arg Arg Ala Ser Arg Asp Tyr Thr Lys Tyr Leu Arg Gly Ser Glu
 1          5          10          15
Glu Met Gly Gly Gly Pro Gly Ala Pro His Glu Gly Pro Leu His Ala
 20          25          30
Pro Pro Pro Pro Ala Pro His Gln Pro Pro Ala Ala Ser Arg Ser Met
 35          40          45
Phe Val Ala Leu Leu Gly Leu Gly Leu Gly Gln Val Val Cys Ser Val
 50          55          60
Ala Leu Phe Phe Tyr Phe Arg Ala Gln Met Asp Pro Asn Arg Ile Ser
 65          70          75          80
Glu Asp Gly Thr His Cys Ile Tyr Arg Ile Leu Arg Leu His Glu Asn
 85          90          95
Ala Asp Phe Gln Asp Thr Thr Leu Glu Ser Gln Asp Thr Lys Leu Ile
100          105          110
Pro Asp Ser Cys Arg Arg Ile Lys Gln Ala Phe Gln Gly Ala Val Gln
115          120          125
Lys Glu Leu Gln His Ile Val Gly Ser Gln His Ile Arg Ala Glu Lys
130          135          140
Ala Met Val Asp Gly Ser Trp Leu Asp Leu Ala Lys Arg Ser Lys Leu
145          150          155          160
Glu Ala Gln Pro Phe Ala His Leu Thr Ile Asn Ala Thr Asp Ile Pro
165          170          175
Ser Gly Ser His Lys Val Ser Leu Ser Ser Trp Tyr His Asp Arg Gly
180          185          190
Trp Ala Lys Ile Ser Asn Met Thr Phe Ser Asn Gly Lys Leu Ile Val
195          200          205
Asn Gln Asp Gly Phe Tyr Tyr Leu Tyr Ala Asn Ile Cys Phe Arg His
210          215          220
His Glu Thr Ser Gly Asp Leu Ala Thr Glu Tyr Leu Gln Leu Met Val
225          230          235          240
Tyr Val Thr Lys Thr Ser Ile Lys Ile Pro Ser Ser His Thr Leu Met
245          250          255
Lys Gly Gly Ser Thr Lys Tyr Trp Ser Gly Asn Ser Glu Phe His Phe
260          265          270
Tyr Ser Ile Asn Val Gly Gly Phe Phe Lys Leu Arg Ser Gly Glu Glu
275          280          285
Ile Ser Ile Glu Val Ser Asn Pro Ser Leu Leu Asp Pro Asp Gln Asp
290          295          300
Ala Thr Tyr Phe Gly Ala Phe Lys Val Arg Asp Ile Asp
305          310          315

```

<210> 3
 <211> 1275
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: GST-RANKL
 (aa127-317)

<400> 3
 atgtccccta tactagggtta ttggaaaatt aagggccttg tgcaaccacac tcgacttctt 60
 ttggaatatc ttgaagaaaa atatgaagag catttgatag agcgcgatga aggtgataaa 120
 tggcgaaaca aaaagtttga attgggtttg gagtttccca atcttcctta ttatatgat 180
 ggtgatgtta aattaacaca gtctatggcc atcatagctt atatagctga caagcacaac 240
 atgttgggtg gttgtccaaa agagcgtgca gagatttcaa tgcttgaagg agcgggtttg 300
 gatattagat acggtgtttc gagaattgca tatagtaaag actttgaaac tctcaaagtt 360
 gattttctta gcaagctacc tgaaatgctg aaaatgttcg aagatcgttt atgtcataaa 420
 acatatttaa atggtgatca tgtaaccat cctgacttca tgttgatga cgctcttgat 480
 gttgttttat acatggaccc aatgtgcctg gatgcggtcc caaaattagt ttgttttaaa 540
 aaacgtattg aagctatccc acaaattgat aagtacttga aatccagcaa gtatatagca 600
 tggcctttgc agggctggca agccacgttt ggtgggtggc accatcctcc aaaatcggat 660
 ctggttccgc gtggatcccc aggaattccc ggtcgcactg tgcaaaagga attacaacat 720
 atcgttggat cacagcacat cagagcagag aaagcgatgg tggatggctc atgggttagat 780
 ctggccaaga ggagcaagct tgaagctcag ccttttgctc atctcactat taatgccacc 840
 gacatcccat ctggttccca taaagtgaat ctgtcctctt ggtaccatga tcgggggttg 900
 gccaaagatc ccaacatgac ttttagcaat ggaaaactaa tagttaatca ggatggcttt 960
 tattacctgt atgccaacat ttgctttcga catcatgaaa cttcaggaga cctagctaca 1020
 gagtatcttc aactaatggt gtacgtcact aaaaccagca tcaaaatccc aagttctcat 1080
 accctgatga aaggaggaag caccaagtat tggtcaggga attctgaatt ccatttttat 1140
 tccataaacg ttggtggatt ttttaagtta cggctctggag aggaaatcag catcgaggtc 1200
 tccaaccctt ccttactgga tccggatcag gatgcaacat actttggggc ttttaaagtt 1260
 cgagatatag attga 1275

<210> 4
 <211> 442
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: GST-RANKL
 (aa127-317)

<400> 4
 Met Ser Pro Ile Leu Gly Tyr Trp Lys Ile Lys Gly Leu Val Gln Pro
 1 5 10 15
 Thr Arg Leu Leu Leu Glu Tyr Leu Glu Glu Lys Tyr Glu Glu His Leu
 20 25 30
 Tyr Glu Arg Asp Glu Gly Asp Lys Trp Arg Asn Lys Lys Phe Glu Leu
 35 40 45
 Gly Leu Glu Phe Pro Asn Leu Pro Tyr Tyr Ile Asp Gly Asp Val Lys
 50 55 60
 Leu Thr Gln Ser Met Ala Ile Ile Arg Tyr Ile Ala Asp Lys His Asn
 65 70 75 80
 Met Leu Gly Gly Cys Pro Lys Glu Arg Ala Glu Ile Ser Met Leu Glu
 85 90 95
 Gly Ala Val Leu Asp Ile Arg Tyr Gly Val Ser Arg Ile Ala Tyr Ser
 100 105 110
 Lys Asp Phe Glu Thr Leu Lys Val Asp Phe Leu Ser Lys Leu Pro Glu
 115 120 125
 Met Leu Lys Met Phe Glu Asp Arg Leu Cys His Lys Thr Tyr Leu Asn
 130 135 140
 Gly Asp His Val Thr His Pro Asp Phe Met Leu Tyr Asp Ala Leu Asp
 145 150 155 160

Val Val Leu Tyr Met Asp Pro Met Cys Leu Asp Ala Phe Pro Lys Leu
 165 170 175
 Val Cys Phe Lys Lys Arg Ile Glu Ala Ile Pro Gln Ile Asp Lys Tyr
 180 185 190
 Leu Lys Ser Ser Lys Tyr Ile Ala Trp Pro Leu Gln Gly Trp Gln Ala
 195 200 205
 Thr Phe Gly Gly Gly Asp His Pro Pro Lys Ser Asp Leu Val Pro Arg
 210 215 220
 Gly Ser Pro Gly Ile Pro Gly Ser Thr Arg Ala Ala Ala Ser Leu Val
 225 230 235 240
 Pro Arg Gly Ser Pro Gly Ile Pro Gly Ser Thr Val Gln Lys Glu Leu
 245 250 255
 Gln His Ile Val Gly Ser Gln His Ile Arg Ala Glu Lys Ala Met Val
 260 265 270
 Asp Gly Ser Trp Leu Asp Leu Ala Lys Arg Ser Lys Leu Glu Ala Gln
 275 280 285
 Pro Phe Ala His Leu Thr Ile Asn Ala Thr Asp Ile Pro Ser Gly Ser
 290 295 300
 His Lys Val Ser Leu Ser Ser Trp Tyr His Asp Arg Gly Trp Ala Lys
 305 310 315 320
 Ile Ser Asn Met Thr Phe Ser Asn Gly Lys Leu Ile Val Asn Gln Asp
 325 330 335
 Gly Phe Tyr Tyr Leu Tyr Ala Asn Ile Cys Phe Arg His His Glu Thr
 340 345 350
 Ser Gly Asp Leu Ala Thr Glu Tyr Leu Gln Leu Met Val Tyr Val Thr
 355 360 365
 Lys Thr Ser Ile Lys Ile Pro Ser Ser His Thr Leu Met Lys Gly Gly
 370 375 380
 Ser Thr Lys Tyr Trp Ser Gly Asn Ser Glu Phe His Phe Tyr Ser Ile
 385 390 395 400
 Asn Val Gly Gly Phe Phe Lys Leu Arg Ser Gly Glu Glu Ile Ser Ile
 405 410 415
 Glu Val Ser Asn Pro Ser Leu Leu Asp Pro Asp Gln Asp Ala Thr Tyr
 420 425 430
 Phe Gly Ala Phe Lys Val Arg Asp Ile Asp
 435 440

<210> 5
 <211> 1236
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: GST-RANKL
 (aa140-317)

<400> 5
 atgtccccta tactaggtta ttggaaaatt aagggccttg tgcaaccac tgcacttctt 60
 ttggaatata ttgaagaaaa atatgaagag catttgatatg agcgcgatga aggtgataaa 120
 tggcgaaaca aaaagtttga attgggtttg gagtttccca atcttcctta ttatatgat 180
 ggtgatgtta aattaacaca gtctatggcc atcatagctt atatagctga caagcacaac 240
 atgttgggtg gttgtccaaa agagcgtgca gagatttcaa tgcttgaagg agcgggtttt 300
 gatattagat acggtgtttc gagaattgca tatagtaaag actttgaaac tctcaaagtt 360
 gattttctta gcaagctacc tgaaatgctg aaaatgttcg aagatcgttt atgtcataaa 420
 acatatttaa atggtgatca tgtaacccat cctgacttca tgttgatatga cgctcttgat 480
 gttgttttat acatggaccc aatgtgcctg gatgcgttcc caaaattagt ttgttttaaa 540
 aaacgtattg aagctatccc acaaattgat aagtacttga aatccagcaa gtatatagca 600
 tggcctttgc agggctggca agccacgttt ggtgggtggcg accatcctcc aaaatcggat 660
 ctggttccgc gtggatcccc aggaattccc gggtcgacta tcagagcaga gaaagcgatg 720
 gtggatggct catgggttaga tctggccaag aggagcaagc ttgaagctca gccttttgct 780
 catctcacta ttaatgccac cgacatccca tctggttccc ataaagttag tctgtcctct 840
 tggtagcatg atcgggggtg ggccaagatc tccaacatga ctttttagcaa tggaaaacta 900
 atagttaatc aggatggctt ttattacctg tatgccaaca tttgctttcg acatcatgaa 960

```

acttcaggag acctagctac agagtatctt caactaatgg tgtacgtcac taaaaccagc 1020
atcaaaatcc caagttctca taccctgatg aaaggaggaa gcaccaagta ttggtcaggg 1080
aattctgaat tccattttta ttccataaac gttgggtggat tttttaagtt acggctctgga 1140
gaggaaatca gcatcgaggt ctccaacccc tccttactgg atccggatca ggatgcaaca 1200
tactttgggg cttttaaggt tcgagatata gattga 1236

```

<210> 6

<211> 429

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: GST-RANKL
(aa140-317)

<400> 6

```

Met Ser Pro Ile Leu Gly Tyr Trp Lys Ile Lys Gly Leu Val Gln Pro
 1          5          10          15
Thr Arg Leu Leu Leu Glu Tyr Leu Glu Glu Lys Tyr Glu Glu His Leu
          20          25          30
Tyr Glu Arg Asp Glu Gly Asp Lys Trp Arg Asn Lys Lys Phe Glu Leu
          35          40          45
Gly Leu Glu Phe Pro Asn Leu Pro Tyr Tyr Ile Asp Gly Asp Val Lys
          50          55          60
Leu Thr Gln Ser Met Ala Ile Ile Arg Tyr Ile Ala Asp Lys His Asn
          65          70          75          80
Met Leu Gly Gly Cys Pro Lys Glu Arg Ala Glu Ile Ser Met Leu Glu
          85          90          95
Gly Ala Val Leu Asp Ile Arg Tyr Gly Val Ser Arg Ile Ala Tyr Ser
          100          105          110
Lys Asp Phe Glu Thr Leu Lys Val Asp Phe Leu Ser Lys Leu Pro Glu
          115          120          125
Met Leu Lys Met Phe Glu Asp Arg Leu Cys His Lys Thr Tyr Leu Asn
          130          135          140
Gly Asp His Val Thr His Pro Asp Phe Met Leu Tyr Asp Ala Leu Asp
          145          150          155          160
Val Val Leu Tyr Met Asp Pro Met Cys Leu Asp Ala Phe Pro Lys Leu
          165          170          175
Val Cys Phe Lys Lys Arg Ile Glu Ala Ile Pro Gln Ile Asp Lys Tyr
          180          185          190
Leu Lys Ser Ser Lys Tyr Ile Ala Trp Pro Leu Gln Gly Trp Gln Ala
          195          200          205
Thr Phe Gly Gly Gly Asp His Pro Pro Lys Ser Asp Leu Val Pro Arg
          210          215          220
Gly Ser Pro Gly Ile Pro Gly Ser Thr Arg Ala Ala Ala Ser Leu Val
          225          230          235          240
Pro Arg Gly Ser Pro Gly Ile Pro Gly Ser Thr Ile Arg Ala Glu Lys
          245          250          255
Ala Met Val Asp Gly Ser Trp Leu Asp Leu Ala Lys Arg Ser Lys Leu
          260          265          270
Glu Ala Gln Pro Phe Ala His Leu Thr Ile Asn Ala Thr Asp Ile Pro
          275          280          285
Ser Gly Ser His Lys Val Ser Leu Ser Ser Trp Tyr His Asp Arg Gly
          290          295          300
Trp Ala Lys Ile Ser Asn Met Thr Phe Ser Asn Gly Lys Leu Ile Val
          305          310          315          320
Asn Gln Asp Gly Phe Tyr Tyr Leu Tyr Ala Asn Ile Cys Phe Arg His
          325          330          335
His Glu Thr Ser Gly Asp Leu Ala Thr Glu Tyr Leu Gln Leu Met Val
          340          345          350
Tyr Val Thr Lys Thr Ser Ile Lys Ile Pro Ser Ser His Thr Leu Met
          355          360          365

```

Lys Gly Gly Ser Thr Lys Tyr Trp Ser Gly Asn Ser Glu Phe His Phe
 370 375 380
 Tyr Ser Ile Asn Val Gly Gly Phe Phe Lys Leu Arg Ser Gly Glu Glu
 385 390 395 400
 Ile Ser Ile Glu Val Ser Asn Pro Ser Leu Leu Asp Pro Asp Gln Asp
 405 410 415
 Ala Thr Tyr Phe Gly Ala Phe Lys Val Arg Asp Ile Asp
 420 425

<210> 7
 <211> 1179
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: GST-RANKL
 (aa159-317)

<400> 7
 atgtccccta tactagggtta ttggaaaatt aagggccttg tgcaaccacac tcgacttctt 60
 ttggaatatc ttgaagaaaa atatgaagag catttgatg agcgcgatga aggtgataaa 120
 tggcgaaaca aaaagtttga attgggtttg gagtttccca atcttcctta ttatattgat 180
 ggtgatgtta aattaacaca gtctatggcc atcatacgtt atatagctga caagcacaac 240
 atgttgggtg gttgtccaaa agagcgtgca gagatttcaa tgcttgaagg agcgggtttt 300
 gatattagat acggtgtttc gagaattgca tatagtaaag actttgaaac tctcaaagtt 360
 gattttctta gcaagctacc tgaaatgctg aaaatgttcg aagatcgttt atgtcataaa 420
 acatatttaa atggtgatca tgtaacccat cctgacttca tggtgtatga cgctcttgat 480
 gttgttttat acatggaccc aatgtgcctg gatgcgttcc caaaattagt ttgtttttaa 540
 aaacgtattg aagctatccc acaaattgat aagtacttga aatccagcaa gtatatagca 600
 tggcctttgc agggctggca agccacgttt ggtgggtggcg accatcctcc aaaatcggat 660
 ctggttccgc gtggatcccc aggaattccc gggtcgacta agcttgaagc tcagcctttt 720
 gctcatctca ctattaatgc caccgacatc ccatctggtt cccataaagt gagtctgtcc 780
 tcttggtacc atgatcgggg ttgggccaag atctccaaca tgacttttag caatggaaaa 840
 ctaatagtta atcaggatgg cttttattac ctgtatgcca acatttgctt tcgacatcat 900
 gaaacttcag gagacctagc tacagagtat cttcaactaa tgggtgtacgt cactaaaacc 960
 agcatcaaaa tccaagttc tcataccctg atgaaaggag gaagcaccaa gtattggtca 1020
 gggaattctg aattccattt ttattccata aacgttggtg gattttttta gttacggtct 1080
 ggagaggaaa tcagcatcga ggtctccaac ccctccttac tggatccgga tcaggatgca 1140
 acatactttg gggcttttaa agttcgagat atagattga 1179

<210> 8
 <211> 410
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: GST-RANKL
 (aa159-317)

<400> 8
 Met Ser Pro Ile Leu Gly Tyr Trp Lys Ile Lys Gly Leu Val Gln Pro
 1 5 10 15
 Thr Arg Leu Leu Leu Glu Tyr Leu Glu Glu Lys Tyr Glu Glu His Leu
 20 25 30
 Tyr Glu Arg Asp Glu Gly Asp Lys Trp Arg Asn Lys Lys Phe Glu Leu
 35 40 45
 Gly Leu Glu Phe Pro Asn Leu Pro Tyr Tyr Ile Asp Gly Asp Val Lys
 50 55 60
 Leu Thr Gln Ser Met Ala Ile Ile Arg Tyr Ile Ala Asp Lys His Asn
 65 70 75 80
 Met Leu Gly Gly Cys Pro Lys Glu Arg Ala Glu Ile Ser Met Leu Glu
 85 90 95

Gly	Ala	Val	Leu	Asp	Ile	Arg	Tyr	Gly	Val	Ser	Arg	Ile	Ala	Tyr	Ser	
			100					105					110			
Lys	Asp	Phe	Glu	Thr	Leu	Lys	Val	Asp	Phe	Leu	Ser	Lys	Leu	Pro	Glu	
		115					120					125				
Met	Leu	Lys	Met	Phe	Glu	Asp	Arg	Leu	Cys	His	Lys	Thr	Tyr	Leu	Asn	
		130				135					140					
Gly	Asp	His	Val	Thr	His	Pro	Asp	Phe	Met	Leu	Tyr	Asp	Ala	Leu	Asp	
145					150					155					160	
Val	Val	Leu	Tyr	Met	Asp	Pro	Met	Cys	Leu	Asp	Ala	Phe	Pro	Lys	Leu	
				165				170						175		
Val	Cys	Phe	Lys	Lys	Arg	Ile	Glu	Ala	Ile	Pro	Gln	Ile	Asp	Lys	Tyr	
			180					185					190			
Leu	Lys	Ser	Ser	Lys	Tyr	Ile	Ala	Trp	Pro	Leu	Gln	Gly	Trp	Gln	Ala	
		195					200					205				
Thr	Phe	Gly	Gly	Gly	Asp	His	Pro	Pro	Lys	Ser	Asp	Leu	Val	Pro	Arg	
	210					215					220					
Gly	Ser	Pro	Gly	Ile	Pro	Gly	Ser	Thr	Arg	Ala	Ala	Ala	Ser	Leu	Val	
225					230					235					240	
Pro	Arg	Gly	Ser	Pro	Gly	Ile	Pro	Gly	Ser	Thr	Lys	Leu	Glu	Ala	Gln	
				245				250						255		
Pro	Phe	Ala	His	Leu	Thr	Ile	Asn	Ala	Thr	Asp	Ile	Pro	Ser	Gly	Ser	
			260					265					270			
His	Lys	Val	Ser	Leu	Ser	Ser	Trp	Tyr	His	Asp	Arg	Gly	Trp	Ala	Lys	
		275					280					285				
Ile	Ser	Asn	Met	Thr	Phe	Ser	Asn	Gly	Lys	Leu	Ile	Val	Asn	Gln	Asp	
		290				295					300					
Gly	Phe	Tyr	Tyr	Leu	Tyr	Ala	Asn	Ile	Cys	Phe	Arg	His	His	Glu	Thr	
305					310					315					320	
Ser	Gly	Asp	Leu	Ala	Thr	Glu	Tyr	Leu	Gln	Leu	Met	Val	Tyr	Val	Thr	
				325				330						335		
Lys	Thr	Ser	Ile	Lys	Ile	Pro	Ser	Ser	His	Thr	Leu	Met	Lys	Gly	Gly	
			340					345					350			
Ser	Thr	Lys	Tyr	Trp	Ser	Gly	Asn	Ser	Glu	Phe	His	Phe	Tyr	Ser	Ile	
		355					360					365				
Asn	Val	Gly	Gly	Phe	Phe	Lys	Leu	Arg	Ser	Gly	Glu	Glu	Ile	Ser	Ile	
	370					375					380					
Glu	Val	Ser	Asn	Pro	Ser	Leu	Leu	Asp	Pro	Asp	Gln	Asp	Ala	Thr	Tyr	
385					390					395					400	
Phe	Gly	Ala	Phe	Lys	Val	Arg	Asp	Ile	Asp							
				405					410							

<210> 9

<211> 587

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 9

```

gtcgactatc agagcagaga aagcgatggt ggatggctca tggtagatc tggccaagag 60
gagcaagctt gaagctcagc cttttgctca tctcactatt aatgccaccg acatcccac 120
tggttcccat aaagtgagtc tgtcctcttg gtaccatgat cgggggttggg ccaagatctc 180
caacatgact tttagcaatg gaaaactaat agttaatcag gatggctttt attacctgta 240
tgccaacatt tgctttcgac atcatgaaac ttcaggagac ctagctacag agtatcttca 300
actaatggtg tacgtcacta aaaccagcat caaaatccca agttctcata ccctgatgaa 360
aggaggaagc accaagtatt ggtcagggaa ttctgaattc catttttatt ccataaacgt 420
tgggtggattt ttttaagttac ggtctggaga ggaaatcagc atcgagggtc ccaaccctc 480
cttactggat ccggatcagg atgcaacata ctttggggct tttaaagttc gagatataga 540
ttgagcccca gtttttggag tgttatgtat ttcttgatg cggccgc 587

```

<210> 10
 <211> 178
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic

<400> 10
 Ile Arg Ala Glu Lys Ala Met Val Asp Gly Ser Trp Leu Asp Leu Ala
 1 5 10 15
 Lys Arg Ser Lys Leu Glu Ala Gln Pro Phe Ala His Leu Thr Ile Asn
 20 25 30
 Ala Thr Asp Ile Pro Ser Gly Ser His Lys Val Ser Leu Ser Ser Trp
 35 40 45
 Tyr His Asp Arg Gly Trp Ala Lys Ile Ser Asn Met Thr Phe Ser Asn
 50 55 60
 Gly Lys Leu Ile Val Asn Gln Asp Gly Phe Tyr Tyr Leu Tyr Ala Asn
 65 70 75 80
 Ile Cys Phe Arg His His Glu Thr Ser Gly Asp Leu Ala Thr Glu Tyr
 85 90 95
 Leu Gln Leu Met Val Tyr Val Thr Lys Thr Ser Ile Lys Ile Pro Ser
 100 105 110
 Ser His Thr Leu Met Lys Gly Gly Ser Thr Lys Tyr Trp Ser Gly Asn
 115 120 125
 Ser Glu Phe His Phe Tyr Ser Ile Asn Val Gly Gly Phe Phe Lys Leu
 130 135 140
 Arg Ser Gly Glu Glu Ile Ser Ile Glu Val Ser Asn Pro Ser Leu Leu
 145 150 155 160
 Asp Pro Asp Gln Asp Ala Thr Tyr Phe Gly Ala Phe Lys Val Arg Asp
 165 170 175
 Ile Asp

<210> 11
 <211> 4970
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic

<400> 11
 acgttatcga ctgcacggtg caccaatgct tctggcgctca ggcagccatc ggaagctgtg 60
 gtatggctgt gcaggtcgta aatcactgca taattcgtgt cgctcaaggc gcactcccgt 120
 tctggataat gttttttgcg cgcacatcat aacggttctg gcaaataattc tgaaatgagc 180
 tgttgacaat taatcatcgg ctctgtataat gtgtggaatt gtgagcggat aacaatttca 240
 cacaggaaac agtattcatg tcccctatac taggttattg gaaaattaag ggccttgtgc 300
 aacccactcg acttcttttg gaatatcttg aagaaaaata tgaagagcat ttgtatgagc 360
 gcgatgaagg tgataaatgg cgaaacaaaa agtttgaatt gggtttggag tttcccaatc 420
 ttccttatta tattgatggt gatgttaaata taacacagtc tatggccatc atacgttata 480
 tagctgacaa gcacaacatg ttgggtggtt gtccaaaaga gcgtgcagag atttcaatgc 540
 ttgaaggagc ggtttttgat attagatacg gtgttttcgag aattgcatat agtaaagact 600
 ttgaaactct caaagttgat tttcttagca agctacctga aatgctgaaa atgttcgaag 660
 atcgtttatg tcataaaaca tatttaaata gtgatcatgt aaccatcct gacttcatgt 720
 tgtatgacgc tcttgatgtt gttttataca tggacccaat gtgcctggat gcgttcccaa 780
 aattagtttg ttttaaaaaa cgtattgaag ctatcccaca aattgataag tacttgaaat 840
 ccagcaagta tatagcatgg cctttgcagg gctggcaagc cacgtttggt ggtggcgacc 900
 atcctccaaa atcggatctg gttccgcgtg gatccccagg aattcccggg tcgactcgag 960
 cggccgcacg gtgactgact gacgatctgc ctgcgcgctt tcggtgatga cggtgaaaac 1020
 ctctgacaca tgcagctccc ggagacggtc acagcttgct tgtaagcgga tgccgggagc 1080
 agacaagccc gtcagggcgc gtcagcgggt gttggcgggt gtcggggcgc agccatgacc 1140
 cagtcacgta gcgatacggt agtgataaat tcttgaagac gaaagggcct cgtgatacgc 1200
 ctatttttat aggttaatgt catgataata atggtttctt agacgtcagg tggcactttt 1260

cggggaaatg	tgcgcggaac	ccctatttgt	ttatttttct	aaatacattc	aaatatgtat	1320
ccgctcatga	gacaataaacc	ctgataaatg	cttcaataat	attgaaaaag	gaagagtatg	1380
agtattcaac	atttccgtgt	cgcccttatt	cccttttttg	cggcattttg	ccttcctgtt	1440
tttgctcacc	cagaaacgct	ggtgaaagta	aaagatgctg	aagatcagtt	gggtgcacga	1500
gtgggttaca	tcgaactgga	tctcaacagc	ggtaagatcc	ttgagagttt	tcgccccgaa	1560
gaacgttttc	caatgatgag	cactttttaa	gttctgctat	gtggcgcggt	attatcccgt	1620
gttgacgccg	ggcaagagca	actcggtcgc	cgcatacact	attctcagaa	tgacttggtt	1680
gagtactcac	cagtcacaga	aaagcatctt	acggatggca	tgacagtaag	agaattatgc	1740
agtgtgccca	taaccatgag	tgataacact	gcggccaact	tacttctgac	aacgatcggg	1800
ggaccgaagg	agctaaccgc	ttttttgcac	aacatggggg	atcatgtaac	tcgccttgat	1860
cgttgggaac	cggagctgaa	tgaagccata	ccaaacgacg	agcgtgacac	cacgatgcct	1920
gcagcaatgg	caacaacggt	gcgcaaacta	ttaactggcg	aactacttac	tctagcttcc	1980
cggcaacaat	taatagactg	gatggaggcg	gataaagttg	caggaccact	tctgcgctcg	2040
gcccttccgg	ctggctgggt	tattgctgat	aaatctggag	ccggtgagcg	tgggtctcgc	2100
ggtatcattg	cagcactggg	gccagatggg	aagccctccc	gtatcgtagt	tatctacacg	2160
acgggggagtc	aggcaactat	ggatgaacga	aatagacaga	tcgctgagat	aggtgcctca	2220
ctgattaagc	attggtaact	gtcagaccaa	gtttactcat	atatacttta	gattgattta	2280
aaacttcatt	tttaatttaa	aaggatctag	gtgaagatcc	tttttgataa	tctcatgacc	2340
aaaatccctt	aacgtgagtt	ttcgttccac	tgagcgtcag	accccgtaga	aaagatcaaa	2400
ggatcttctt	gagatccttt	ttttctgcgc	gtaatctgct	gcttgcaaac	aaaaaaacca	2460
ccgctaccag	cgggtggtttg	tttgccggat	caagagctac	caactctttt	tccgaaggta	2520
actggcttca	gcagagcgca	gataccaaat	actgtccttc	tagtgtagcc	gtagttaggc	2580
caccacttca	agaactctgt	agcaccgcct	acatacctcg	ctctgctaata	cctgttacca	2640
gtggctgctg	ccagtggcga	taagtcgtgt	cttaccgggt	tggactcaag	acgatagtta	2700
ccggataagg	cgcagcggtc	gggctgaacg	gggggttcgt	gcacacagcc	cagcttggag	2760
cgaacgacct	acaccgaact	gagataccta	cagcgtgagc	tatgagaaag	cgccacgctt	2820
cccgaaggga	gaaaggcgga	caggtatccg	gtaagcggca	gggtcggaac	aggagagcgc	2880
acgagggagc	ttccaggggg	aaacgcctgg	tatctttata	gtcctgtcgg	gtttcgccac	2940
ctctgacttg	agcgtcgatt	tttgtgatgc	tcgtcagggg	ggcggagcct	atggaaaaac	3000
gccagcaacg	cggccttttt	acggttcctg	gcctttttgt	ggccttttgc	tcacatgttc	3060
tttctgctgt	tatccccctga	ttctgtggat	aaccgtatta	ccgcctttga	gtgagctgat	3120
accgctcgcc	gcagccgaac	gaccgagcgc	agcgagtcag	tgagcgagga	agcggaagag	3180
cgcctgatgc	ggtattttct	ccttacgcac	ctgtgcggta	tttcacaccg	cataaattcc	3240
gacaccatcg	aatggtgcaa	aacctttcgc	ggtatggcat	gatagcgccc	ggaagagagt	3300
caattcaggg	tggtagaatgt	gaaaccagta	acgttatacg	atgtcgcaga	gtatgccggg	3360
gtctcttata	agaccgtttc	ccgcgtgggtg	aaccaggcca	gccacgtttc	tgcgaaaacg	3420
cgggaaaaag	tggaaagcggc	gatggcggag	ctgaattaca	ttcccaaccg	cgtggcacia	3480
caactggcgg	gcaaacagtc	gttgctgatt	ggcgttgcca	cctccagtct	ggccctgcac	3540
gcgcctgcgc	aaattgtcgc	ggcgattaaa	tctcgcgcgc	atcaactggg	tgccagcgtg	3600
gtggtgtcga	tggtagaacg	aagcggcgtc	gaagcctgta	aagcggcggt	gcacaatctt	3660
ctcgcgcaac	gcgtcagtg	gctgatcatt	aactatccgc	tggatgacca	ggatgccatt	3720
gctgtggaag	ctgcctgcac	taatgttccg	gcgttatattc	ttgatgtctc	tgaccagaca	3780
cccatcaaca	gtattatttt	ctcccatgaa	gacggtacgc	gactgggcgt	ggagcatctg	3840
gtcgcattgg	gtcaccagca	aatcgcgctg	ttagcggggc	cattaagtctc	tgtctcggcg	3900
cgtctgcgtc	tggctggctg	gcataaatat	ctcactcgca	atcaaattca	gccgatagcg	3960
gaacgggaag	gcgactggag	tgccatgtcc	ggttttcaac	aaaccatgca	aatgctgaat	4020
gagggcatcg	ttcccactgc	gatgctgggt	gccaacgatc	agatggcgct	gggcgcaatg	4080
cgcgccatta	ccgagtcctg	gctgcgcgtt	ggtgcggata	tctcggtagt	gggatacgac	4140
gataccgaag	acagctcatg	ttatatcccg	ccgttaacca	ccatcaaaca	ggattttcgc	4200
ctgctggggc	aaaccagcgt	ggaccgcttg	ctgcaactct	ctcagggcca	ggcgggtgaag	4260
ggcaatcagc	tggttggccgt	ctcactgggtg	aaaagaaaaa	ccaccctggc	gcccataacg	4320
caaaccgcct	ctccccgcgc	gttggccgat	tcattaatgc	agctggcacg	acaggtttcc	4380
cgactggaaa	gcgggcagtg	agcgcaacgc	aattaatgtg	agtttagctca	ctcattaggc	4440
acccagggct	ttacacttta	tgcttccggc	tcgtatgttg	tgtggaattg	tgagcggata	4500
acaatttcac	acaggaaaca	gctatgacca	tgattacgga	ttcactggcc	gtcgttttac	4560
aacgtcgtga	ctgggaaaac	cctggcggtta	cccaacttaa	tcgccttgca	gcacatcccc	4620
ctttcgccag	ctggcgtaat	agcgaagagg	cccgaccgga	tcgccttccc	caacagttgc	4680
gcagcctgaa	tggcgaatgg	cgttttgcc	ggtttccggc	accagaagcg	gtgccggaaa	4740
gctggctgga	gtgcgatctt	cctgaggccg	atactgtcgt	cgtccctcca	aactggcaga	4800
tgcacggtta	cgatgcgccc	atctacacca	acgtaacctc	tcccattacg	gtcaatccgc	4860
cgtttgttcc	cacggagaaat	ccgacggggt	gttactcgtc	cacatttaata	gttgatgaaa	4920
gctggctaca	ggaaggccag	acgcgaatta	tttttgatgg	cgttggaatt		4970

<210> 12
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: CpG
oligonucleotide

<400> 12
tccatgacgt tcctgatgct

20

<210> 13
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: GpC
oligonucleotide

<400> 13
tccatgagct tcctgatgct

20

72813-305

CLAIMS:

1. A method for detection of a bacterial infectious disease or sepsis with the use of RANKL (receptor activator of NF- κ B ligand) and/or OPG (osteoprotegerin) as a marker in a biological sample from a subject, comprising measuring RANKL
5 and/or OPG in the biological sample from the subject, and determining that the subject is affected with the bacterial infectious disease or sepsis when the concentration of soluble RANKL in the biological sample is lower than in a biological sample of a normal subject, or when the concentration of OPG in the biological sample is higher than in the biological sample of a normal subject.
- 10 2. The method according to claim 1, comprising measuring soluble RANKL in the biological sample from the subject and determining that the subject is affected with the bacterial infectious disease or sepsis when the concentration of soluble RANKL in the biological sample is lower than in a biological sample of a normal subject.
- 15 3. The method according to claim 1, comprising measuring OPG in the biological sample from the subject and determining that the subject is affected with the bacterial infectious disease or sepsis when the concentration of OPG in the biological sample is higher than in a biological sample of a normal subject.
4. The method according to claim 1, comprising measuring
20 membrane-type RANKL existing on a cell in the biological sample from the subject by a flow cytometric method.
5. The method according to claim 1, comprising measuring
membrane-type RANKL existing on a cell in the biological sample from the subject by a flow cytometric method and then determining that the subject is affected with the
25 bacterial infectious disease or sepsis when the ratio of the amount of membrane-type RANKL measured to the concentration of OPG is lower than in a biological sample of a normal subject.

72813-305

6. The method according to claim 4 or 5, in which the cell in the biological sample is a peripheral blood cell.

7. A detection reagent for detection of a bacterial infectious disease or sepsis with the use of RANKL (receptor activator of NF- κ B ligand) and/or OPG

5 (osteoprotegerin) as a marker, comprising means for measuring RANKL and/or OPG in a biological sample from a subject using an anti-RANKL antibody and/or anti-OPG antibody.

8. A detection reagent for detection of a bacterial infectious disease or sepsis with the use of RANKL (receptor activator of NF- κ B ligand) and/or OPG

10 (osteoprotegerin) as a marker, comprising an anti-RANKL antibody and/or an anti-OPG antibody.

9. A composition for prevention or treatment of an infectious disease, an allergic disease, or an autoimmune disease, comprising RANKL (receptor activator of NF- κ B ligand) and M-CSF (macrophage colony stimulating factor) as active

15 ingredients, and a carrier, a diluent or an excipient.

10. The composition according to claim 9, in which the composition for prevention or treatment of an infectious disease, an allergic disease, or an autoimmune disease is a combination preparation for simultaneous administration of RANKL and M-CSF.

20 11. The composition according to claim 9 or claim 10, in which the composition is a kit comprising a drug that contains RANKL and a drug that contains M-CSF.

12. The composition according to claim 9, for prevention or treatment of sepsis.

25 13. An immunosuppressive agent, comprising RANKL (receptor activator of NF- κ B ligand) and M-CSF (macrophage colony stimulating factor) as active ingredients, and a carrier, a diluent or an excipient.

72813-305

14. The immunosuppressive agent according to claim 13, in which the immunosuppressive agent is a combination preparation for simultaneous administration of RANKL and M-CSF.

15. The immunosuppressive agent according to claim 13 or claim 14, in
5 which the immunosuppressive agent is a kit comprising a drug that contains RANKL and a drug that contains M-CSF.

Fig. 1




Fig. 2




Fig. 3




Fig. 4




Fig. 5




Fig. 6




Fig. 7




Fig. 8





Fig. 9

A



B





Fig. 10

A



B





Fig. 11

A



B




Fig. 12





Fig. 13

A



B




Fig. 14




Fig. 15




Fig. 16




Fig. 17




Fig. 18




Fig. 19

10 20 30 40 50 60
gtcgactATCAGAGCAGAGAAAGCGATGGTGGATGGCTCATGGTTAGATCTGGCCAAGAGGAGCAAG
*Sa*II I R A E K A M V D G S W L D L A K R S K

70 80 90 100 110 120
 CTTGAAGCTCAGCCTTTTGCTCATCTCACTATTAATGCCACCGACATCCCATCTGGTTCC
 L E A Q P F A H L T I N A T D I P S G S

130 140 150 160 170 180
 CATAAAGTGAGTCTGTCCTCTTGGTACCATGATCGGGGTTGGGCCAAGATCTCCAACATG
 H K V S L S S W Y H D R G W A K I S N M

190 200 210 220 230 240
 ACTTTTAGCAATGGAAAATAAGTTAATCAGGATGGCTTTTATTACCTGTATGCCAAC
 T F S N G K L I V N Q D G F Y Y L Y A N

250 260 270 280 290 300
 ATTTGCTTTCGACATCATGAACTTCAGGAGACCTAGCTACAGAGTATCTTCAACTAATG
 I C F R H H E T S G D L A T E Y L Q L M

310 320 330 340 350 360
 GTGTACGTCACTAAAACCAGCATCAAAATCCCAAGTTCTCATACCCTGATGAAAGGAGGA
 V Y V T K T S I K I P S S H T L M K G G

370 380 390 400 410 420
 AGCACCAAGTATTGGTCAGGGAATTCTGAATTCCATTTTATTCCATAAACGTTGGTGGA
 S T K Y W S G N S E F H F Y S I N V G G

430 440 450 460 470 480
 TTTTTTAAGTTACGGTCTGGAGAGGAAATCAGCATCGAGGTCTCCAACCCCTCCTTACTG
 F F K L R S G E E I S I E V S N P S L L

490 500 510 520 530 540
 GATCCGGATCAGGATGCAACATACTTTGGGGCTTTTAAAGTTTCGAGATATAGATTGAGCC
 D P D Q D A T Y F G A F K V R D I D *

550 560 570 580
 CCAGTTTTTGGAGTGTTATGTATTTCTGGATgcggccgc
*Not*I

Fig. 20




Fig. 21A

```

1   ACGTTATCGA CTGCACGGTG CACCAATGCT TCTGGCGTCA GGCAGCCATC GGAAGCTGTG
61  GTATGGCTGT GCAGGTCGTA AATCACTGCA TAATTCGTGT CGCTCAAGGC GCACTCCCGT
121 TCTGGATAAT GTTTTTTGCG CCGACATCAT AACGGTTCTG GCAAATATTC TGAAATGAGC
181 TGTTGACAAT TAATCATCGG CTCGTATAAT GTGTGGAATT GTGAGCGGAT AACAAATTTCA

      tac promoter
241 CACAGGAAAC AGTATTCATG TCCCCTATAC TAGGTTATTG GAAAATTAAG GGCCTTGTGC
301 AACCCACTCG ACTTCTTTTG GAATATCTTG AAGAAAAATA TGAAGAGCAT TTGTATGAGC
361 GCGATGAAGG TGATAAATGG CGAAACAAAA AGTTTGAATT GGGTTTGGAG TTTCCCAATC
421 TTCCTTATTA TATTGATGGT GATGTTAAAT TAACACAGTC TATGGCCATC ATACGTTATA
481 TAGCTGACAA GCACAACATG TTGGGTGGTT GTCCAAAAGA GCGTGCAGAG ATTTCAATGC
541 TTGAAGGAGC GGTTTTGGAT ATTAGATACG GTGTTTCGAG AATTGCATAT AGTAAAGACT
601 TTGAAACTCT CAAAGTTGAT TTTCTTAGCA AGCTACCTGA AATGCTGAAA ATGTTCAAG
661 ATCGTTTATG TCATAAAACA TATTTAAATG GTGATCATGT AACCCATCCT GACTTCATGT
721 TGTATGACGC TCTTGATGTT GTTTTATACA TGGACCCAAT GTGCCTGGAT GCGTTCCCAA
781 AATTAGTTTG TTTTAAAAAA CGTATTGAAG CTATCCCACA AATTGATAAG TACTTGAAAT
841 CCAGCAAGTA TATAGCATGG CCTTTCGAGG GCTGGCAAGC CACGTTTGGT GGTGGCGACC
901 ATCCTCCAAA ATCGGATCTG GTTCCGCGTG GATCCCCAGG AATTCCCGGG TCGACTCGAG
961 CGGCCGCATC GTGACTGACT GACGATCTGC CTCGCGCGTT TCGGTGATGA CCGTGAAAAC
1021 CTCTGACACA TGCAGCTCCC GGAGACGGTC ACAGCTTGTC TGTAAGCGGA TGCCGGGAGC
1081 AGACAAGCCC GTCAGGGCGC GTCAGCGGGT GTTGGCGGGT GTCGGGGCGC AGCCATGACC
1141 CAGTCACGTA GCGATAGCGG AGTGTATAAT TCTTGAAGAC GAAAGGGCCT CGTGATACGC
1201 CTATTTTAT AGGTTAATGT CATGATAATA ATGGTTTCTT AGACGTCAGG TGGCACTTTT
1261 CGGGGAAATG TGC GCGGAAC CCCTATTTGT TTATTTTCT AAATACATTC AAATATGTAT
1321 CCGCTCATGA GACAATAACC CTGATAAATG CTTCAATAAT ATTGAAAAAG GAAGAGTATG
      β-lactamase initiation codon
1381 AGTATTCAAC ATTTCCGTGT CGCCCTTATT CCCTTTTTTG CGGCATTTTG CCTTCCTGTT
1441 TTTGCTCACC CAGAAACGCT GGTGAAAGTA AAAGATGCTG AAGATCAGTT GGTGACACGA
1501 GTGGGTACA TCGAACTGGA TCTCAACAGC GGTAAGATCC TTGAGAGTTT TCGCCCCGAA
1561 GAACGTTTTT CAATGATGAG CACTTTTAAA GTTCTGCTAT GTGGCGCGGT ATTATCCCGT
1621 GTTGACGCCG GGCAAGAGCA ACTCGGTCGC CGCATACACT ATTCTCAGAA TGACTTGGTT
1681 GAGTACTCAC CAGTCACAGA AAAGCATCTT ACGGATGGCA TGACAGTAAG AGAATTATGC
1741 AGTGCTGCCA TAACCATGAG TGATAACACT GCGGCCAACT TACTTCTGAC AACGATCGGA
1801 GGACCGAAGG AGCTAACCGC TTTTTTGAC AACATGGGGG ATCATGTAAC TCGCCTTGAT
1861 CGTTGGGAAC CGGAGCTGAA TGAAGCCATA CCAAACGACG AGCGTGACAC CACGATGCCT
1921 GCAGCAATGG CAACAACGTT GCGCAAACTA TTAAGTGGCG AACTACTTAC TCTAGCTTCC
1981 CGGCAACAAT TAATAGACTG GATGGAGGCG GATAAAGTTG CAGGACCACT TCTGCGCTCG
2041 GCCCTTCCGG CTGGCTGGTT TATTGCTGAT AAATCTGGAG CCGGTGAGCG TGGGTCTCGC
2101 GGTATCATTG CAGCACTGGG GCCAGATGGT AAGCCCTCCC GTATCGTAGT TATCTACACG
2161 ACGGGGAGTC AGGCAACTAT GGATGAACGA AATAGACAGA TCGCTGAGAT AGGTGCCTCA
2221 CTGATTAAGC ATTGGTAACT GTCAGACCAA GTTTACTCAT ATATACTTTA GATTGATTTA
      β-lactamase termination codon
2281 AAAC TTCATT TTTAATTTAA AAGGATCTAG GTGAAGATCC TTTTGTATAA TCTCATGACC
2341 AAAATCCCTT AACGTGAGTT TTCGTTCCAC TGAGCGTCAG ACCCGTAGA AAAGATCAAA
2401 GGATCTTCTT GAGATCCTTT TTTTCTGCGC GTAATCTGCT GCTTGCAAAC AAAAAACCA
2461 CCGCTACCAG CGGTGGTTTG TTTGCCGGAT CAAGAGCTAC CAACTCTTTT TCCGAAGGTA
2521 ACTGGCTTCA GCAGAGCGCA GATACCAAAT ACTGTCCTTC TAGTGTAGCC GTAGTTAGGC
2581 CACCACTTCA AGAACTCTGT AGCACC GCCT ACATACCTCG CTCTGCTAAT CCTGTTACCA
2641 GTGGCTGCTG CCAGTGGCGA TAAGTCGTGT CTTACCGGGT TGGACTCAAG ACGATAGTTA

```

Fig. 21B

```

2701 CCGGATAAGG CGCAGCGGTC GGGCTGAACG GGGGGTTCGT GCACACAGCC CAGCTTGGAG
2761 CGAACGACCT ACACCGAACT GAGATACCTA CAGCGTGAGC TATGAGAAAG CGCCACGCTT
2821 CCCGAAGGGA GAAAGGCGGA CAGGTATCCG GTAAGCGGCA GGGTCGGAAC AGGAGAGCGC
2881 ACGAGGGAGC TTCCAGGGGG AAACGCCTGG TATCTTTATA GTCCTGTCGG GTTTCGCCAC
2941 CTCTGACTTG AGCGTCGATT TTTGTGATGC TCGTCAGGGG GGCGGAGCCT ATGGAAAAAC
3001 GCCAGCAACG CGGCCTTTTT ACGGTTCTCT GCCTTTTGCT GGCCTTTTGC TCACATGTTC
3061 TTTCCTGCGT TATCCCCTGA TTCTGTGGAT AACCGTATTA CCGCCTTTGA GTGAGCTGAT
3121 ACCGCTCGCC GCAGCCGAAC GACCGAGCGC AGCGAGTCAG TGAGCGAGGA AGCGGAAGAG
3181 CGCCTGATGC GGTATTTTCT CCTTACGCAT CTGTGCGGTA TTTCACACCG CATAAATTCC
3241 GACACCATCG AATGGTGCAA AACCTTTCGC GGTATGGCAT GATAGCGCCC GGAAGAGAGT
3301 CAATTCAGGG TGGTGAATGT GAAACCAGTA ACGTTATACG ATGTCGCAGA GTATGCCGGT
                                lacIq initiation codon
3361 GTCTCTTATC AGACCGTTTC CCGCGTGGTG AACCAGGCCA GCCACGTTTC TGCGAAAACG
3421 CGGGAAAAAG TGGAAGCGGC GATGGCGGAG CTGAATTACA TTCCAACCG CGTGGCACAA
3481 CAACTGGCGG GCAAACAGTC GTTGCTGATT GCGGTTGCCA CCTCCAGTCT GGCCCTGCAC
3541 GCGCCGTCGC AAATTGTCGC GGCGATTAAA TCTCGCGCCG ATCAACTGGG TGCCAGCGTG
3601 GTGGTGTCGA TGGTAGAACG AAGCGGCGTC GAAGCCTGTA AAGCGGCGGT GCACAATCTT
3661 CTCGCGCAAC GCGTCAGTGG GCTGATCATT AACTATCCGC TGGATGACCA GGATGCCATT
3721 GCTGTGGAAG CTGCCTGCAC TAATGTTCCG GCGTTATTTT TTGATGTCTC TGACCAGACA
3781 CCCATCAACA GTATTATTTT CTCCCATGAA GACGGTACGC GACTGGGCGT GGAGCATCTG
3841 GTCGCATTGG GTCACCAGCA AATCGCGCTG TTAGCGGGCC CATTAAAGTT TGTCTCGGCG
3901 CGTCTGCGTC TGGCTGGCTG GCATAAATAT CTCACTCGCA ATCAAATTCA GCCGATAGCG
3961 GAACGGGAAG GCGACTGGAG TGCCATGTCC GGTTTTCAAC AAACCATGCA AATGCTGAAT
4021 GAGGGCATCG TTCCCACTGC GATGCTGGTT GCCAACGATC AGATGGCGCT GGGCGCAATG
4081 CGCGCCATTA CCGAGTCCGG GCTGCGCGTT GGTGCGGATA TCTCGGTAGT GGGATACGAC
4141 GATACCGAAG ACAGCTCATG TTATATCCCG CCGTTAACCA CCATCAAACA GGATTTTTCG
4201 CTGCTGGGGC AAACCAGCGT GGACCGCTTG CTGCAACTCT CTCAGGGCCA GGCGGTGAAG
4261 GGCAATCAGC TGTTGCCCGT CTCACTGGTG AAAAGAAAAA CCACCCTGGC GCCCAATACG
4321 CAAACCGCCT CTCCCCGCGC GTTGGCCGAT TCATTAATGC AGCTGGCACG ACAGGTTTCC
4381 CGACTGGAAA GCGGGCAGTG AGCGCAACGC AATTAATGTG AGTTAGCTCA CTCATTAGGC
                                lacIq termination codon
4441 ACCCCAGGCT TTACACTTTA TGCTTCCGGC TCGTATGTTG TGTGGAATTG TGAGCGGATA
4501 ACAATTTTAC ACAGGAAACA GCTATGACCA TGATTACGGA TTCACTGGCC GTCGTTTTAC
4561 AACGTCGTGA CTGGGAAAAC CCTGGCGTTA CCCAACTTAA TCGCCTTGCA GCACATCCCC
4621 CTTTCGCCAG CTGGCGTAAT AGCGAAGAGG CCCGCACCGA TCGCCCTTCC CAACAGTTGC
4681 GCAGCCTGAA TGGCGAATGG CGCTTTGCCT GGTTCCTGGC ACCAGAAGCG GTGCCGAAA
4741 GCTGGCTGGA GTGCGATCTT CCTGAGGCCG ATACTGTCGT CGTCCCCTCA AACTGGCAGA
4801 TGCACGGTTA CGATGCGCCC ATCTACACCA ACGTAACCTA TCCCATTACG GTCAATCCGC
4861 CGTTTGTTCC CACGGAGAAT CCGACGGGTT GTTACTCGCT CACATTTAAT GTTGATGAAA
4921 GCTGGCTACA GGAAGGCCAG ACGCGAATTA TTTTGTATGG CGTTGGAATT

```

Position of tac promoter:183-211

β -lactamase gene:1, 378-2, 238

lacIq gene:3, 319-4, 401

Fig. 22

Method for preparation of recombinant DNA
Expression of sRANKL in *E. coli*




Fig. 23

